id.exposure,id.outcome,outcome,exposure,method,nsnp,b,se,pval,lo_ci,up_ci,or,or_lci95,or_uci95,OR_CI,effect_direction,egger_intercept,egger_intercept_se,egger_intercept_pval,Q,Q_df,Q_pval,snp_r2.exposure,snp_r2.outcome,correct_causal_direction,steiger_pval,Fst,total_r2
prot-a-70,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),RAC-alpha/beta/gamma serine/threonine-protein kinase,Wald ratio,1,-0.025224775224775224,0.02122877122877123,0.23474072223825299,-0.06683316683316684,0.016383616383616392,0.9750907111600161,0.9353512359293334,1.0165185637947667,0.98 [0.94:1.02],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-70,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),RAC-alpha/beta/gamma serine/threonine-protein kinase,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-71,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),RAC-alpha/beta/gamma serine/threonine-protein kinase,Wald ratio,1,-0.028252449305080883,0.019366598313966737,0.14461368473578445,-0.06621098200045569,0.00970608339029392,0.9721429190166441,0.935933378362903,1.0097533401867402,0.97 [0.94:1.01],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-71,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),RAC-alpha/beta/gamma serine/threonine-protein kinase,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-d-ApoA1,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Apolipoprotein A1,Inverse variance weighted,66,0.04068285462813832,0.02683581874108155,0.1295216758492968,-0.011915350104381522,0.09328105936065816,1.0415217393618637,0.9881553565694535,1.0977702305124506,1.04 [0.99:1.1],overlaps null,-3.863348242248329e-4,0.0025601888191501246,0.8805285029838673,146.80496785860873,65,2.89733919081184e-8,0.07270161006941549,5.219392132247018e-4,TRUE,0,142.4871698433583,0.07875396556859365
met-d-ApoA1,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Apolipoprotein A1,MR Egger,66,0.04619593475164483,0.0454523792539962,0.3132853833704784,-0.04289072858618772,0.13528259808947737,1.0472795893217313,0.9580160681179853,1.1448602739665295,1.05 [0.96:1.14],overlaps null,-3.863348242248329e-4,0.0025601888191501246,0.8805285029838673,146.7527534929963,64,1.9133348728967495e-8,0.07270161006941549,5.219392132247018e-4,TRUE,0,142.4871698433583,0.07875396556859365
met-d-ApoA1,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Apolipoprotein A1,Weighted median,66,0.058639015015237245,0.028012911967284452,0.03632369987474823,0.003733707559359721,0.11354432247111476,1.0603923859126232,1.0037406865285359,1.1202415396653334,1.06 [1:1.12],positive,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ieu-a-1,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Adiponectin,Inverse variance weighted,11,-0.054050182812045426,0.041146397107631356,0.18897859374742673,-0.1346971211430029,0.02659675551891203,0.947384562887418,0.8739805818441806,1.026953605883893,0.95 [0.87:1.03],overlaps null,-0.007897106136869175,0.0039429611520485535,0.07620350867592596,15.318080432424715,10,0.1208883624571377,0.07718011210014392,5.516875604595938e-5,TRUE,0,105.43260097901171,0.02826559025561699
ieu-a-1,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Adiponectin,MR Egger,11,0.02345632912613589,0.05290326474016745,0.6679566040109169,-0.0802340697645923,0.12714672801686408,1.0237335924298252,0.9229002980469242,1.1355836274916764,1.02 [0.92:1.14],overlaps null,-0.007897106136869175,0.0039429611520485535,0.07620350867592596,10.595571180395812,9,0.3044516394632155,0.07718011210014392,5.516875604595938e-5,TRUE,0,105.43260097901171,0.02826559025561699
ieu-a-1,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Adiponectin,Weighted median,11,-0.02616145214463103,0.043068970059604667,0.5435645419989097,-0.11057663346145617,0.05825372917219411,0.9741777938171559,0.8953177162647579,1.0599839104332232,0.97 [0.9:1.06],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-c-841,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Albumin,Inverse variance weighted,3,0.10467347764651196,0.062163252679300264,0.09221102017370651,-0.017166497604916564,0.22651345289794048,1.1103479977169555,0.9829800071924583,1.254219482607104,1.11 [0.98:1.25],overlaps null,0.053976298750608345,0.04345498091748639,0.4315186687884122,2.1468974985607625,2,0.3418276045477698,0.012291569836283354,1.8362545804008765e-5,TRUE,1.5517967432808948e-45,80.2916172020224,0.01254760753862574
met-c-841,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Albumin,MR Egger,3,-0.09545723915392662,0.1719290834493491,0.6773377992876772,-0.43243824271465087,0.24152376440679763,0.908957228602813,0.6489249277389239,1.2731877111087118,0.91 [0.65:1.27],overlaps null,0.053976298750608345,0.04345498091748639,0.4315186687884122,0.6040355268790012,1,0.4370424190600281,0.012291569836283354,1.8362545804008765e-5,TRUE,1.5517967432808948e-45,80.2916172020224,0.01254760753862574
met-c-841,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Albumin,Weighted median,3,0.1287183036205046,0.06944687265744696,0.06381376733040547,-0.0073975667880914475,0.26483417402910064,1.1373696861120053,0.9926297278629622,1.3032148509913566,1.14 [0.99:1.3],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-d-Albumin,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Albumin,Inverse variance weighted,26,0.017286610330884286,0.08700263486136071,0.842504736099146,-0.15323855399738273,0.18781177465915128,1.0174368884635676,0.8579250359512686,1.2066063800768085,1.02 [0.86:1.21],overlaps null,0.008674035776069879,0.006928661657258842,0.22266800559086433,185.07888043024744,25,2.208300055507435e-26,0.022756214719991875,5.85597569797137e-4,TRUE,5.459442893086009e-274,99.05661207573866,0.022722006668076614
met-d-Albumin,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Albumin,MR Egger,26,-0.11547156517258327,0.13655407058224261,0.4061220562275194,-0.3831175435137788,0.15217441316861224,0.8909459057699674,0.6817327613120105,1.1643632990156003,0.89 [0.68:1.16],overlaps null,0.008674035776069879,0.006928661657258842,0.22266800559086433,173.7335742096153,24,1.1441054396997507e-24,0.022756214719991875,5.85597569797137e-4,TRUE,5.459442893086009e-274,99.05661207573866,0.022722006668076614
met-d-Albumin,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Albumin,Weighted median,26,-0.07444660557784843,0.0461135297776488,0.10643635255077544,-0.16482912394204008,0.01593591278634321,0.9282570364838643,0.8480386012010106,1.016063566636593,0.93 [0.85:1.02],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ukb-d-30600_irnt,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Albumin,Inverse variance weighted,186,-0.0362280218651687,0.043063926783271186,0.40020147699819547,-0.12063331836038023,0.04817727463004283,0.9644203594800199,0.8863589115512553,1.049356663150992,0.96 [0.89:1.05],overlaps null,9.14629575640756e-4,0.0022024624237049735,0.6784237815709445,746.5582345071355,185,1.72731085808571e-68,0.043053563306594586,0.002368679774095358,TRUE,0,85.0763839756563,0.043073613998040196
ukb-d-30600_irnt,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Albumin,MR Egger,186,-0.06592447132780081,0.08352567690494872,0.43096894534557584,-0.22963479806150028,0.09778585540589867,0.9362015716829876,0.7948238207060709,1.1027266168785592,0.94 [0.79:1.1],overlaps null,9.14629575640756e-4,0.0022024624237049735,0.6784237815709445,745.8591776805243,184,1.113773139774367e-68,0.043053563306594586,0.002368679774095358,TRUE,0,85.0763839756563,0.043073613998040196
ukb-d-30600_irnt,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Albumin,Weighted median,186,-0.0162115778744904,0.04000619850083485,0.6853109159506918,-0.09462372693612671,0.062200571187145906,0.9839191225144531,0.9097151713917172,1.0641757663209899,0.98 [0.91:1.06],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ieu-b-107,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),apolipoprotein A-I,Inverse variance weighted,264,0.06514364040281383,0.02626069024769361,0.013114224416706772,0.013672687517334352,0.1166145932882933,1.0673123225459629,1.0137665861702425,1.123686269994263,1.07 [1.01:1.12],positive,-9.179973878132955e-4,0.0012416016988621385,0.4603470313607687,686.9958219865072,263,1.2481105308717468e-39,0.08914914276657057,0.0023564310717779273,TRUE,0,171.47077817020093,0.10540777721348657
ieu-b-107,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),apolipoprotein A-I,MR Egger,264,0.08935803227365396,0.04199276735281249,0.03427584422318556,0.007052208262141493,0.17166385628516645,1.0934720845467885,1.007077133641366,1.1872786698669076,1.09 [1.01:1.19],positive,-9.179973878132955e-4,0.0012416016988621385,0.4603470313607687,685.5653943557708,262,1.1994567763296828e-39,0.08914914276657057,0.0023564310717779273,TRUE,0,171.47077817020093,0.10540777721348657
ieu-b-107,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),apolipoprotein A-I,Weighted median,264,0.050488357204293816,0.03106628556093742,0.10412385934754166,-0.010401562495143526,0.11137827690373116,1.0517846175702865,0.9896523466809021,1.1178176714960768,1.05 [0.99:1.12],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-c-842,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Apolipoprotein A-I,Inverse variance weighted,11,0.04620978195490102,0.027896327242893815,0.09762411665593859,-0.008467019441170856,0.10088658335097289,1.0472940913154765,0.9915687248143613,1.106151178688753,1.05 [0.99:1.11],overlaps null,0.01310302539765435,0.008995168145205904,0.17919115239637154,17.69993462666375,10,0.06024124517587002,0.03881354605696007,7.11153504389129e-5,TRUE,8.081147586683971e-153,77.0017658406783,0.03935594553423642
met-c-842,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Apolipoprotein A-I,MR Egger,11,-0.04723317012114853,0.06938798616561728,0.5131843708097557,-0.1832336230057584,0.08876728276346135,0.9538649588503305,0.8325736246617998,1.0928263072135354,0.95 [0.83:1.09],overlaps null,0.01310302539765435,0.008995168145205904,0.17919115239637154,14.323041384019511,9,0.1112891145683516,0.03881354605696007,7.11153504389129e-5,TRUE,8.081147586683971e-153,77.0017658406783,0.03935594553423642
met-c-842,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Apolipoprotein A-I,Weighted median,11,0.04741012927419204,0.027657102294492353,0.08648984669525953,-0.006797791223012974,0.10161804977139705,1.0485519627607731,0.9932252614943125,1.1069605871233326,1.05 [0.99:1.11],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ukb-d-30630_irnt,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Apoliprotein A,Inverse variance weighted,222,0.06189797937719343,0.02412319638727012,0.01029051739878236,0.014616514458143999,0.10917944429624285,1.063853804163764,1.014723858064402,1.1153624778199316,1.06 [1.01:1.12],positive,-0.0013814400260338563,0.001276815472397458,0.28046288113952783,589.4894172170987,221,2.623917458974084e-35,0.07527540442709078,0.0020547711199682813,TRUE,0,171.6448063278531,0.09703784729333688
ukb-d-30630_irnt,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Apoliprotein A,MR Egger,222,0.09135149019948446,0.036367043742811016,0.012725223378349776,0.020072084463574877,0.16263089593539404,1.0956540492452425,1.0202748833437234,1.1766023208306995,1.1 [1.02:1.18],positive,-0.0013814400260338563,0.001276815472397458,0.28046288113952783,586.3694041186247,220,4.274614468982371e-35,0.07527540442709078,0.0020547711199682813,TRUE,0,171.6448063278531,0.09703784729333688
ukb-d-30630_irnt,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Apoliprotein A,Weighted median,222,0.06527522930943173,0.02792380809637019,0.019407012215987944,0.01054456544054616,0.12000589317831731,1.06745277824851,1.010600355291525,1.127503496138953,1.07 [1.01:1.13],positive,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-132,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Apolipoprotein E (isoform E2),Wald ratio,1,-0.09911003236245955,0.03640776699029126,0.0064844521966554046,-0.1704692556634304,-0.027750809061488677,0.9056430524963712,0.8432690149764978,0.9726307073642497,0.91 [0.84:0.97],negative,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-132,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Apolipoprotein E (isoform E2),NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-131,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Apolipoprotein E (isoform E3),Wald ratio,1,0.0020784259387557156,0.01621172232229458,0.8979866418423419,-0.029696549812941668,0.033853401690453096,1.0020805873631413,0.9707400601120038,1.0344329494903073,1 [0.97:1.03],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-131,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Apolipoprotein E (isoform E3),NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-127,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Apolipoprotein B,Wald ratio,1,0.0035169988276670576,0.02743259085580305,0.8979866418423419,-0.05025087924970691,0.057284876905041034,1.0035231907248812,0.9509908107092722,1.058957439947876,1 [0.95:1.06],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-127,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Apolipoprotein B,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-c-843,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Apolipoprotein B,Inverse variance weighted,20,0.003108388146952026,0.02702246783483702,0.9084215289223266,-0.04985564880932854,0.056072425103232584,1.0031132241948613,0.9513667455117297,1.0576742831318604,1 [0.95:1.06],overlaps null,0.0036298216847661575,0.006608692854124677,0.589583892594435,55.3687490842231,19,2.04062984626738e-5,0.06876637281847174,1.7403912447494957e-4,TRUE,6.38135178047567e-271,74.89558402093132,0.07071718421634327
met-c-843,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Apolipoprotein B,MR Egger,20,-0.01859528659870509,0.048161421474515326,0.7039458404300384,-0.11299167268875512,0.07580109949134495,0.9815765390457458,0.8931580976905183,1.0787479892936909,0.98 [0.89:1.08],overlaps null,0.0036298216847661575,0.006608692854124677,0.589583892594435,54.456080048459995,18,1.5577536254646266e-5,0.06876637281847174,1.7403912447494957e-4,TRUE,6.38135178047567e-271,74.89558402093132,0.07071718421634327
met-c-843,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Apolipoprotein B,Weighted median,20,-0.0023153149808197485,0.022501091119164995,0.9180440059307575,-0.04641745357438314,0.04178682361274364,0.9976873632934955,0.954643359714715,1.0426721819685478,1 [0.95:1.04],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ieu-b-108,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),apolipoprotein B,Inverse variance weighted,177,0.008649334415325708,0.024979852822037664,0.7291530250801901,-0.04031117711586812,0.05760984594651953,1.0086868479860447,0.9604905099780625,1.0593016242536955,1.01 [0.96:1.06],overlaps null,0.0017869804951571118,0.00132733380292893,0.17994922194431973,433.4048514283423,176,1.0101603816949311e-23,0.06145698502892919,0.0013893936132673246,TRUE,0,240.59553912341835,0.08978558558416183
ieu-b-108,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),apolipoprotein B,MR Egger,177,-0.02255058220985046,0.034032212423456804,0.5084427471058055,-0.08925371855982579,0.04415255414012488,0.9777017816258716,0.9146134897162979,1.0451417834334726,0.98 [0.91:1.05],overlaps null,0.0017869804951571118,0.00132733380292893,0.17994922194431973,428.96201723700614,175,2.4310405611836957e-23,0.06145698502892919,0.0013893936132673246,TRUE,0,240.59553912341835,0.08978558558416183
ieu-b-108,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),apolipoprotein B,Weighted median,177,0.017108329050098292,0.028311771244133112,0.5456553426864232,-0.03838274258840261,0.07259940068859919,1.017255514680229,0.9623445401541373,1.0752996863073527,1.02 [0.96:1.08],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-d-ApoB,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Apolipoprotein B,Inverse variance weighted,52,0.017368174526267644,0.02442775616759786,0.4770832238525434,-0.03051022756222416,0.06524657661475945,1.0175198782691808,0.9699505117872668,1.0674221932881507,1.02 [0.97:1.07],overlaps null,0.002089200891659149,0.0024733697143681037,0.40231435166327534,117.28221734259493,51,3.895764870079596e-7,0.060914987589111055,3.788033198406861e-4,TRUE,0,188.4836080671642,0.08129412305145553
met-d-ApoB,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Apolipoprotein B,MR Egger,52,-0.0044984446738032795,0.03564057179000041,0.9000663675453102,-0.07435396538220408,0.06535707603459752,0.9955116581737276,0.9283430343807019,1.0675401493381487,1 [0.93:1.07],overlaps null,0.002089200891659149,0.0024733697143681037,0.40231435166327534,115.63219024967275,50,4.0918857152741235e-7,0.060914987589111055,3.788033198406861e-4,TRUE,0,188.4836080671642,0.08129412305145553
met-d-ApoB,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Apolipoprotein B,Weighted median,52,0.004022566009603268,0.024652269240828847,0.8703828219962579,-0.04429588170242127,0.052341013721627805,1.0040306673873873,0.9566708541915766,1.0537350193512758,1 [0.96:1.05],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-275,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Basigin,Wald ratio,1,0.020134228187919462,0.04078471863706763,0.6215386296568242,-0.0598038203407331,0.10007227671657203,1.0203382889949408,0.941949306753333,1.1052507990875908,1.02 [0.94:1.11],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-275,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Basigin,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ieu-b-35,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),C-Reactive protein level,Inverse variance weighted,53,0.03126898611932134,0.04092269647529539,0.44480832586988006,-0.04893949897225762,0.1114774712109003,1.0317629964885053,0.9522387393781534,1.1179285581451135,1.03 [0.95:1.12],overlaps null,-3.768761083949359e-4,0.0032901370525619997,0.9092537887432426,262.9728024277896,52,5.864194729452385e-30,0.03172797569493132,8.038021722405962e-4,TRUE,0,166.0407128758088,0.04128657678290181
ieu-b-35,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),C-Reactive protein level,MR Egger,53,0.036489822922850634,0.06151764668744679,0.5556953638473136,-0.08408476458454507,0.15706441043024633,1.0371637486685517,0.9193533241896634,1.1700709762488257,1.04 [0.92:1.17],overlaps null,-3.768761083949359e-4,0.0032901370525619997,0.9092537887432426,262.9051632726061,51,2.6295259465190364e-30,0.03172797569493132,8.038021722405962e-4,TRUE,0,166.0407128758088,0.04128657678290181
ieu-b-35,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),C-Reactive protein level,Weighted median,53,0.02665640397889265,0.030175686550905592,0.37703446554794373,-0.03248794166088231,0.0858007496186676,1.027014863911911,0.9680341226446569,1.0895892056102436,1.03 [0.97:1.09],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-670,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),C-reactive protein,Inverse variance weighted,3,0.042437759093834765,0.030230170452996016,0.16037205076782807,-0.016813374994037428,0.10168889318170696,1.0433511152338408,0.9833271809528848,1.1070390107642694,1.04 [0.98:1.11],overlaps null,-0.11946837843782197,0.060000088781908975,0.29629976040211076,3.9665934445005147,2,0.13761481085465174,0.04378392349385333,2.8612355415897278e-5,TRUE,3.684293394430284e-32,49.93279320192895,0.043460151453047685
prot-a-670,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),C-reactive protein,MR Egger,3,0.6717557055784036,0.3167877456667058,0.28053011641196945,0.050851724071660165,1.292659687085147,1.9576713997350903,1.052166870696772,3.642461491685994,1.96 [1.05:3.64],positive,-0.11946837843782197,0.060000088781908975,0.29629976040211076,0.001968108919757591,1,0.9646147564989515,0.04378392349385333,2.8612355415897278e-5,TRUE,3.684293394430284e-32,49.93279320192895,0.043460151453047685
prot-a-670,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),C-reactive protein,Weighted median,3,0.017325077123562127,0.026832443841300343,0.5184889141913269,-0.03526651280538654,0.06991666705251079,1.0174760267501763,0.965348104339167,1.072418809710115,1.02 [0.97:1.07],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ukb-d-30710_irnt,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),C-reactive protein,Inverse variance weighted,180,0.04277008346642281,0.029921509976924873,0.15288663814422507,-0.01587607608834994,0.10141624302119556,1.0436979038585643,0.9842492845193487,1.1067372175441466,1.04 [0.98:1.11],overlaps null,-3.601067030218152e-4,0.0015433977166068632,0.8157804501561715,644.4448049132857,179,8.48678215269974e-54,0.050299345618834895,0.0021951761949978,TRUE,0,174.79561264571916,0.08221071287530522
ukb-d-30710_irnt,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),C-reactive protein,MR Egger,180,0.0498908022266975,0.04279557677107477,0.2452577007493407,-0.03398852824460905,0.13377013269800406,1.0511563061806934,0.9665825929729769,1.1431300212276123,1.05 [0.97:1.14],overlaps null,-3.601067030218152e-4,0.0015433977166068632,0.8157804501561715,644.247771615286,178,4.7750394958250543e-54,0.050299345618834895,0.0021951761949978,TRUE,0,174.79561264571916,0.08221071287530522
ukb-d-30710_irnt,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),C-reactive protein,Weighted median,180,0.024800247337368277,0.02802282544269916,0.3761557302271609,-0.030124490530322075,0.07972498520505863,1.0251103315533197,0.9703247297890061,1.0829891886666239,1.03 [0.97:1.08],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-b-51,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),cathepsin D,Inverse variance weighted,2,0.03462598809271486,0.019239069616811287,0.07189624218186055,-0.0030825883562352607,0.07233456454166498,1.0352324471218668,0.996922157941039,1.0750149457880869,1.04 [1:1.08],overlaps null,NA,NA,NA,1.3123047907255712,1,0.2519777841000719,0.04491915770494122,1.625401472936346e-5,TRUE,2.8544005823939375e-34,79.95059209061124,0.04503115572282335
prot-a-495,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cyclin-dependent kinase inhibitor 1B,Wald ratio,1,-0.023338607594936705,0.016811708860759493,0.16506540826067562,-0.05628955696202531,0.009612341772151898,0.9769316312917674,0.9452653880854358,1.0096586887111674,0.98 [0.95:1.01],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-495,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cyclin-dependent kinase inhibitor 1B,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-2218,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),"Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A",Wald ratio,1,0.054382597568777995,0.04670505438259757,0.24426860628509978,-0.03715930902111323,0.14592450415866923,1.055888505258993,0.9635226252753553,1.157108827848702,1.06 [0.96:1.16],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-2218,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),"Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A",NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-346,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Calcium/calmodulin-dependent protein kinase type 1,Inverse variance weighted,3,-0.02280632624864035,0.006453624272531605,4.095087558687523e-4,-0.035455429822802295,-0.010157222674478404,0.9774517721940801,0.9651657508799054,0.9898941877023036,0.98 [0.97:0.99],negative,-0.02363442091755319,0.03882997975343842,0.6519179945529003,1.0738666347643702,2,0.5845380993536934,0.2905704839534254,4.069910910917918e-5,TRUE,1.7055428504049037e-253,962.121209780234,0.46679506533379456
prot-a-346,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Calcium/calmodulin-dependent protein kinase type 1,MR Egger,3,9.79523348766708e-4,0.039608072358124864,0.9842593488042484,-0.07665229847315802,0.07861134517069143,1.000980003238437,0.9262118428971219,1.0817837998585311,1 [0.93:1.08],overlaps null,-0.02363442091755319,0.03882997975343842,0.6519179945529003,0.7033944525757677,1,0.40164545427398257,0.2905704839534254,4.069910910917918e-5,TRUE,1.7055428504049037e-253,962.121209780234,0.46679506533379456
prot-a-346,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Calcium/calmodulin-dependent protein kinase type 1,Weighted median,3,-0.02287695059581617,0.0065806993078586454,5.082491413911713e-4,-0.03577512123921912,-0.009978779952413227,0.9773827427383819,0.9648572449898996,0.99007084287666,0.98 [0.96:0.99],negative,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-347,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Calcium/calmodulin-dependent protein kinase type 1D,Inverse variance weighted,3,-0.024401024670530864,0.016497873179758333,0.13912945728001286,-0.0567368561028572,0.007934806761795466,0.9758942735958346,0.9448426662380948,1.0079663707705067,0.98 [0.94:1.01],overlaps null,-0.016862267728994924,0.014358122005770066,0.44904666054417697,1.6466984446669028,2,0.43895901844174845,0.0728296371905048,1.1495207364086071e-5,TRUE,9.182914775644851e-55,84.64450553078537,0.07151176314786167
prot-a-347,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Calcium/calmodulin-dependent protein kinase type 1D,MR Egger,3,0.03632452139777658,0.05427559119121531,0.6245239888201652,-0.07005563733700543,0.1427046801325586,1.0369923180884038,0.9323419454398603,1.1533891326395609,1.04 [0.93:1.15],overlaps null,-0.016862267728994924,0.014358122005770066,0.44904666054417697,0.26746848525106387,1,0.6050350112152536,0.0728296371905048,1.1495207364086071e-5,TRUE,9.182914775644851e-55,84.64450553078537,0.07151176314786167
prot-a-347,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Calcium/calmodulin-dependent protein kinase type 1D,Weighted median,3,-0.028327861342480384,0.01896215196890517,0.13519758803757098,-0.06549367920153452,0.008837956516573754,0.9720696105026845,0.9366049668321551,1.0088771265636214,0.97 [0.94:1.01],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-348,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Calcium/calmodulin-dependent protein kinase type II subunit alpha,Wald ratio,1,-0.023551142923112448,0.019395058877857307,0.22463863892378028,-0.06156545832371277,0.014463172477487875,0.9767240208699616,0.9402913938264666,1.0145682702275658,0.98 [0.94:1.01],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-348,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Calcium/calmodulin-dependent protein kinase type II subunit alpha,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-349,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Calcium/calmodulin-dependent protein kinase type II subunit beta,Wald ratio,1,-0.018149466192170817,0.015124555160142349,0.23013934044341655,-0.04779359430604982,0.011494661921708185,0.9820142434589577,0.9533305396229782,1.0115609794034814,0.98 [0.95:1.01],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-349,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Calcium/calmodulin-dependent protein kinase type II subunit beta,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-c-875,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cholesterol esters in large HDL,Inverse variance weighted,13,0.05908853991322906,0.02106882020876313,0.0050387018817466605,0.017793652304053324,0.10038342752240478,1.0608691658459286,1.0179529024803966,1.1055947522722547,1.06 [1.02:1.11],positive,0.0036160342676674504,0.008161328567391974,0.6663028642717806,18.353265708155753,12,0.10537759690759356,0.0648910965646224,1.0964659056097613e-4,TRUE,1.4247152353745608e-243,104.94930175813884,0.06615518445625727
met-c-875,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cholesterol esters in large HDL,MR Egger,13,0.036234288780204224,0.05600380729678253,0.5309032728303089,-0.07353317352148954,0.146001751081898,1.0368987517785704,0.9291053235848635,1.1571982143978676,1.04 [0.93:1.16],overlaps null,0.0036160342676674504,0.008161328567391974,0.6663028642717806,18.031468871014493,11,0.08085329099984821,0.0648910965646224,1.0964659056097613e-4,TRUE,1.4247152353745608e-243,104.94930175813884,0.06615518445625727
met-c-875,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cholesterol esters in large HDL,Weighted median,13,0.05039642606173446,0.02292626116934291,0.027935109100335802,0.005460954169822355,0.09533189795364656,1.0516879302530229,1.0054758923599227,1.1000238902236787,1.05 [1.01:1.1],positive,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-c-881,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cholesterol esters in large VLDL,Inverse variance weighted,25,0.015834283349546736,0.022119795708959254,0.4740887882055042,-0.0275205162400134,0.05918908293910687,1.0159603099156163,0.9728547230277117,1.0609758342042133,1.02 [0.97:1.06],overlaps null,0.0024308107657341244,0.005021100170034822,0.6328791802685553,69.6294434502216,24,2.4877748741414e-6,0.10270486471872796,2.2994533295246907e-4,TRUE,0,90.95343554997712,0.105657415004876
met-c-881,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cholesterol esters in large VLDL,MR Egger,25,0.0029336511312572193,0.03486409522410195,0.9336689989770951,-0.0653999755079826,0.07126727777049705,1.00293795849681,0.9366927342889496,1.073868208615201,1 [0.94:1.07],overlaps null,0.0024308107657341244,0.005021100170034822,0.6328791802685553,68.92707252015269,23,1.7788868350500652e-6,0.10270486471872796,2.2994533295246907e-4,TRUE,0,90.95343554997712,0.105657415004876
met-c-881,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cholesterol esters in large VLDL,Weighted median,25,0.0036665945853382774,0.018113067873781273,0.8395820335379456,-0.03183501844727302,0.03916820761794958,1.003673324766366,0.9686663809805083,1.0399453956767821,1 [0.97:1.04],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-c-887,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cholesterol esters in large VLDL,Inverse variance weighted,12,-0.1108036839253861,0.021033107321318446,1.3787259865239992e-7,-0.15202857427517025,-0.06957879357560195,0.8951144570378394,0.8589637361242956,0.9327866328948313,0.9 [0.86:0.93],negative,-0.0017164075940272916,0.005997785760562073,0.7805860480652702,9.259006785997178,11,0.5979982883089735,0.04154318433727714,1.1889190639346523e-4,TRUE,5.2748315161173836e-148,69.97993272180987,0.04244046154729363
met-c-887,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cholesterol esters in large VLDL,MR Egger,12,-0.09713283372848162,0.05219653293391849,0.09237753320042107,-0.19943803827896187,0.0051723708219986175,0.9074354600916394,0.8191909777232537,1.0051857706249139,0.91 [0.82:1.01],overlaps null,-0.0017164075940272916,0.005997785760562073,0.7805860480652702,9.17711148997372,10,0.5153817095246411,0.04154318433727714,1.1889190639346523e-4,TRUE,5.2748315161173836e-148,69.97993272180987,0.04244046154729363
met-c-887,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cholesterol esters in large VLDL,Weighted median,12,-0.10175410886741111,0.02855672292804977,3.663225306514763e-4,-0.15772528580638867,-0.045782931928433565,0.9032516259300248,0.8540843788448709,0.9552492938094356,0.9 [0.85:0.96],negative,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-c-899,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cholesterol esters in medium HDL,Inverse variance weighted,7,0.07079998364381335,0.05882913907746317,0.22878871095003062,-0.044505128948014464,0.18610509623564114,1.0733665135371937,0.9564706943925714,1.2045488472751045,1.07 [0.96:1.2],overlaps null,-0.0027711081455814167,0.01913644554424689,0.8905186835333804,22.61294814735237,6,9.370357287808908e-4,0.02069469750326165,8.535823360959436e-5,TRUE,4.4955224670879185e-73,59.17815405770613,0.02104994549606213
met-c-899,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cholesterol esters in medium HDL,MR Egger,7,0.09472998553594796,0.17732568600717397,0.61608198568358985,-0.252828359038113,0.44228833011000895,1.0993619714129481,0.7766011669561154,1.5562643936347058,1.1 [0.78:1.56],overlaps null,-0.0027711081455814167,0.01913644554424689,0.8905186835333804,22.51850857298582,5,4.1714225875239723e-4,0.02069469750326165,8.535823360959436e-5,TRUE,4.4955224670879185e-73,59.17815405770613,0.02104994549606213
met-c-899,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cholesterol esters in medium HDL,Weighted median,7,0.06954404259518153,0.03891667331678089,0.07393770711468702,-0.0067326371057090245,0.14582072229607207,1.0720192746760027,0.9932899763177048,1.1569887471705262,1.07 [0.99:1.16],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-c-905,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cholesterol esters in medium LDL,Inverse variance weighted,24,0.0011335118703612122,0.018910947779427863,0.9522038572168547,-0.0359319457773174,0.03819896951803982,1.0011341545377421,0.9647059435623215,1.0389379292937377,1 [0.96:1.04],overlaps null,-0.0010349058177427858,0.0046142736750873605,0.8246065330958401,45.86172319732171,23,0.003111864071430535,0.0973209153939637,1.5714257383727672e-4,TRUE,0,89.28137176236022,0.10017192616269002
met-c-905,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cholesterol esters in medium LDL,MR Egger,24,0.006484280434471416,0.03069512323188587,0.8346384308131309,-0.05367816110002489,0.06664672196896772,1.0065053488941642,0.9477370760816606,1.0689177862925294,1.01 [0.95:1.07],overlaps null,-0.0010349058177427858,0.0046142736750873605,0.8246065330958401,45.75709933150452,22,0.0021247893357213073,0.0973209153939637,1.5714257383727672e-4,TRUE,0,89.28137176236022,0.10017192616269002
met-c-905,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cholesterol esters in medium LDL,Weighted median,24,-1.1140614868688711e-4,0.018236520699664416,0.9951257866233955,-0.03585498672002914,0.03563217442265537,0.9998886000567476,0.9647801892792021,1.036274608074599,1 [0.96:1.04],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-c-910,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cholesterol esters in medium VLDL,Inverse variance weighted,14,-0.07520807794200302,0.024049069243453763,0.0017643418818661459,-0.1223442536591724,-0.02807190222483364,0.9275504634558084,0.8848437053815655,0.9723184524278011,0.93 [0.88:0.97],negative,0.0011752887095970819,0.008018291181895296,0.8859003777409595,21.0054336877333,13,0.07282122427955375,0.053537526627753025,1.1715519999119252e-4,TRUE,2.1781348318860523e-197,79.86292168778593,0.05487222537626808
met-c-910,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cholesterol esters in medium VLDL,MR Egger,14,-0.08445318580074772,0.06785088930991634,0.23700725785903734,-0.21744092884818372,0.0485345572466883,0.9190146773060245,0.8045751306958058,1.0497316470290188,0.92 [0.8:1.05],overlaps null,0.0011752887095970819,0.008018291181895296,0.8859003777409595,20.96789327590096,12,0.05085258543087162,0.053537526627753025,1.1715519999119252e-4,TRUE,2.1781348318860523e-197,79.86292168778593,0.05487222537626808
met-c-910,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cholesterol esters in medium VLDL,Weighted median,14,-0.07008504728254514,0.027377549415165025,0.010468843794214686,-0.12374504413626858,-0.01642505042882169,0.9323145257172287,0.883605092466472,0.9837091052033781,0.93 [0.88:0.98],negative,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-c-943,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cholesterol esters in very large HDL,Inverse variance weighted,13,0.07347255507447913,0.02354979015633309,0.0018092379659725851,0.027314966368066268,0.11963014378089198,1.0762389989673944,1.0276914400337462,1.1270799169644774,1.08 [1.03:1.13],positive,3.0717386659167293e-4,0.008254385708576093,0.97098160641895,18.052744870152925,12,0.11409836568601209,0.04891839391555753,1.1750267023103213e-4,TRUE,4.0614022117580485e-179,76.47810438266569,0.04908926012245622
met-c-943,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cholesterol esters in very large HDL,MR Egger,13,0.07119168770086515,0.06604231017568235,0.304118432055688,-0.05825124024347225,0.20063461564520255,1.0737870379104244,0.9434128943741334,1.22217812546368,1.07 [0.94:1.22],overlaps null,3.0717386659167293e-4,0.008254385708576093,0.97098160641895,18.050472417206937,11,0.08041683971340424,0.04891839391555753,1.1750267023103213e-4,TRUE,4.0614022117580485e-179,76.47810438266569,0.04908926012245622
met-c-943,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cholesterol esters in very large HDL,Weighted median,13,0.053254256127741255,0.02591213343261397,0.03986103438600095,0.002466474599817879,0.10404203765566464,1.0546977744032118,1.002469518850635,1.1096471008978686,1.05 [1:1.11],positive,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-d-Total_CE,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Total esterified cholesterol,Inverse variance weighted,61,0.03698289839035638,0.025614328113707605,0.14878501017501858,-0.013221184712510527,0.08718698149322329,1.0376752747689284,0.9868658312432785,1.0911006762796003,1.04 [0.99:1.09],overlaps null,-4.8410855760544713e-4,0.0024543729147303455,0.8443151063820582,132.69669772340472,60,2.0566174366399135e-7,0.05865853344309517,4.305884472401514e-4,TRUE,0,154.31493160788077,0.07565113340698283
met-d-Total_CE,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Total esterified cholesterol,MR Egger,61,0.042775627456007194,0.0391060115712587,0.2784720120068332,-0.03387215522365986,0.11942341013567426,1.0437036901249122,0.9666950836546314,1.1268469357081534,1.04 [0.97:1.13],overlaps null,-4.8410855760544713e-4,0.0024543729147303455,0.8443151063820582,132.60925448318113,59,1.3832370078822706e-7,0.05865853344309517,4.305884472401514e-4,TRUE,0,154.31493160788077,0.07565113340698283
met-d-Total_CE,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Total esterified cholesterol,Weighted median,61,0.014824630597553836,0.026726972818632195,0.5791208966252366,-0.03756023612696526,0.06720949732207293,1.01493506045286,0.9631364003669716,1.0695195161806443,1.01 [0.96:1.07],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-879,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Dynactin-associated protein,Inverse variance weighted,2,0.03164539538046546,0.034122664590933674,0.35371833945697767,-0.035235027217764545,0.09852581797869546,1.0321514347369802,0.965378499369992,1.103542895273561,1.03 [0.97:1.1],overlaps null,NA,NA,NA,1.3697431294493556,1,0.24185602251519342,0.03155056072184482,7.609421281330616e-6,TRUE,6.822626980134574e-24,53.17767634385489,0.031240966840827333
prot-a-908,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Epidermal growth factor,Wald ratio,1,-0.04333082140165787,0.02486812358703843,0.08143423698753752,-0.0920723436322532,0.005410700828937451,0.957594544890777,0.9120391669323151,1.0054253651067449,0.96 [0.91:1.01],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-908,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Epidermal growth factor,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-928,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),ELAV-like protein 1,Wald ratio,1,-0.024627606752730884,0.01688182720953327,0.14461368473578448,-0.05771598808341609,0.008460774577954324,0.975673178488357,0.9439179933292664,1.0084966680887384,0.98 [0.94:1.01],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-928,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),ELAV-like protein 1,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-905,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Ephrin-B2,Wald ratio,1,-0.048691418137553254,0.055690809494826535,0.38194567659846634,-0.15784540474741326,0.06046256847230675,0.9524750008642178,0.8539817932950956,1.0623278322724188,0.95 [0.85:1.06],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-905,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Ephrin-B2,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-962,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Ephrin type-B receptor 2,Wald ratio,1,0.033710629921259845,0.02829724409448819,0.23353412768512005,-0.021751968503937007,0.08917322834645669,1.0342852722103208,0.978482899533192,1.0932700252825314,1.03 [0.98:1.09],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-962,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Ephrin type-B receptor 2,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-1320,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Histone deacetylase 8,Wald ratio,1,-0.003235082674335011,0.041337167505391806,0.9376205435203785,-0.08425593098490294,0.07778576563623293,0.9967701445672477,0.9191959752573142,1.080891069853176,1 [0.92:1.08],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-1320,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Histone deacetylase 8,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-1397,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Intercellular adhesion molecule 1,Inverse variance weighted,3,9.820863847733066e-4,0.019353785260904477,0.9595296010988843,-0.03695133272659947,0.03891550549614608,1.000982568789515,0.9637230359802557,1.039682632470543,1 [0.96:1.04],overlaps null,-0.03950903622418574,0.026016150319834095,0.37071497187519475,26.174252623243277,2,2.0717304957995383e-6,0.2805055300831925,8.087241441787332e-5,TRUE,2.3411967937165693e-240,3130.476198109417,0.7401569488696367
prot-a-1397,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Intercellular adhesion molecule 1,MR Egger,3,0.039355351191054606,0.029412025215700185,0.40858240869640783,-0.018292218231717755,0.09700292061382697,1.040140032985956,0.981874068928178,1.1018635917343527,1.04 [0.98:1.1],overlaps null,-0.03950903622418574,0.026016150319834095,0.37071497187519475,7.916592788374246,1,0.004898343551240677,0.2805055300831925,8.087241441787332e-5,TRUE,2.3411967937165693e-240,3130.476198109417,0.7401569488696367
prot-a-1397,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Intercellular adhesion molecule 1,Weighted median,3,0.004358832145351349,0.005544036819004876,0.431738661982508,-0.006507480019898208,0.015225144310600906,1.0043683456717862,0.9935136477737992,1.0153416372767854,1 [0.99:1.02],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-1426,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Interferon alpha/beta receptor 1,Wald ratio,1,0.04867103900586814,0.03348291335864687,0.1460549490439056,-0.016955471177079726,0.114297549188816,1.0498749260281346,0.9831874638406589,1.1210856533878832,1.05 [0.98:1.12],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-1426,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Interferon alpha/beta receptor 1,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-1443,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Insulin-like growth factor I,Inverse variance weighted,3,-0.018605149236224233,0.022924811333495953,0.4170369064059888,-0.0635377794498763,0.026327480977427837,0.9815668581598835,0.9384386649344412,1.0266771106507773,0.98 [0.94:1.03],overlaps null,-0.01309924622884821,0.010295171900340546,0.4240565276389154,1.8117256939864197,2,0.4041929779022418,0.03721010842626091,7.535831037907303e-6,TRUE,4.6674705545869155e-28,42.21179732044945,0.03698857426777589
prot-a-1443,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Insulin-like growth factor I,MR Egger,3,0.04259845451186204,0.053285661417106514,0.5706657270652336,-0.06184144186566672,0.1470383508893908,1.043518790449411,0.9400319246833831,1.158398387786426,1.04 [0.94:1.16],overlaps null,-0.01309924622884821,0.010295171900340546,0.4240565276389154,0.19280562650533323,1,0.6605917056493034,0.03721010842626091,7.535831037907303e-6,TRUE,4.6674705545869155e-28,42.21179732044945,0.03698857426777589
prot-a-1443,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Insulin-like growth factor I,Weighted median,3,-0.01585427971984056,0.025821686894676225,0.539221367618447,-0.06646478603340597,0.03475622659372484,0.9842707378132602,0.9356958648391218,1.0353672830241991,0.98 [0.94:1.04],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ukb-d-30770_irnt,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),IGF-1,Inverse variance weighted,318,0.06753739359777337,0.027642500568880738,0.01455586328069963,0.013358092482767127,0.12171669471277963,1.0698702651482863,1.0134477103970205,1.1294340818038415,1.07 [1.01:1.13],positive,-7.253476635995056e-4,0.001503625195179473,0.6298563334057681,967.2025778756753,317,6.076213646085487e-67,0.08356626327904101,0.0031243111426969214,TRUE,0,105.22406103870784,0.08753534522247032
ukb-d-30770_irnt,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),IGF-1,MR Egger,318,0.09053692712516186,0.05512798421394811,0.10152166739382237,-0.017513921934176432,0.19858777618450013,1.0947619333061738,0.9826385553405584,1.219679081491871,1.09 [0.98:1.22],overlaps null,-7.253476635995056e-4,0.001503625195179473,0.6298563334057681,966.490833733747,316,4.407828462144296e-67,0.08356626327904101,0.0031243111426969214,TRUE,0,105.22406103870784,0.08753534522247032
ukb-d-30770_irnt,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),IGF-1,Weighted median,318,0.07353920259044511,0.03191713621405345,0.02121891396218403,0.010981615610900358,0.13609678956998986,1.0763107300135826,1.0110421348818557,1.1457927890193618,1.08 [1.01:1.15],positive,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-1444,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Insulin-like growth factor 1 receptor,Wald ratio,1,-0.19779715465810002,0.03579623680587425,3.282847540610213e-8,-0.26795777879761357,-0.12763653051858648,0.8205362782198808,0.7649400771108803,0.8801732371218667,0.82 [0.76:0.88],negative,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-1444,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Insulin-like growth factor 1 receptor,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ebi-a-GCST90010149,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Lipoprotein lipase levels,Inverse variance weighted,3,0.006437156568707921,0.013610555070478711,0.6362465164532234,-0.020239531369430352,0.03311384450684619,1.0064579195887475,0.9799639130935645,1.033668209990703,1.01 [0.98:1.03],overlaps null,0.01217942488828348,0.01623280479860622,0.5902134754942843,0.8100294238238351,2,0.666966998426562,0.11081870455960946,3.2224485518870962e-6,TRUE,3.8553868511148576e-35,56.923663453025846,0.11634716279363165
ebi-a-GCST90010149,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Lipoprotein lipase levels,MR Egger,3,-0.029636562722489115,0.049968607377235526,0.6591962917759435,-0.12757503318187075,0.06830190773689251,0.9707982937304108,0.8802273670962056,1.0706885088325941,0.97 [0.88:1.07],overlaps null,0.01217942488828348,0.01623280479860622,0.5902134754942843,0.2470838220902253,1,0.6191359744716689,0.11081870455960946,3.2224485518870962e-6,TRUE,3.8553868511148576e-35,56.923663453025846,0.11634716279363165
ebi-a-GCST90010149,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Lipoprotein lipase levels,Weighted median,3,-7.094512015888338e-5,0.01470208375829156,0.9961498113269945,-0.028887029286410338,0.028745139046092574,0.9999290573963866,0.9715262122768159,1.029162267770844,1 [0.97:1.03],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ukb-d-30790_irnt,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Lipoprotein A,Inverse variance weighted,20,1.0726469690947302e-4,0.00950407513323249,0.9909951228833207,-0.018520722564226207,0.018735251958045155,1.0001072704499727,0.981649732081397,1.0189118579863867,1 [0.98:1.02],overlaps null,-0.006074164896669073,0.0052228516685884595,0.2600172606570357,30.72778787675105,19,0.043236263841426106,0.034547544453679586,1.0567430785387455e-4,TRUE,0,7039.240290698945,0.28047139457405407
ukb-d-30790_irnt,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Lipoprotein A,MR Egger,20,0.007908393857800204,0.011561839368780002,0.5026817292986916,-0.014752811305008601,0.03056959902060901,1.0079397478031216,0.985355478236592,1.0310416470404848,1.01 [0.99:1.03],overlaps null,-0.006074164896669073,0.0052228516685884595,0.2600172606570357,28.580201902442816,18,0.05375719044324311,0.034547544453679586,1.0567430785387455e-4,TRUE,0,7039.240290698945,0.28047139457405407
ukb-d-30790_irnt,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Lipoprotein A,Weighted median,20,0.010690856380530186,0.008855972236949195,0.22735831743324236,-0.006666849203890237,0.02804856196495061,1.0107482077819252,0.9933553249306948,1.0284456265492414,1.01 [0.99:1.03],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ieu-b-110,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),LDL cholesterol,Inverse variance weighted,160,0.06072481107231794,0.031939688094627626,0.057271410045729484,-0.0018769775931522029,0.12332659973778809,1.0626064564171813,0.9981247828276947,1.1312538278236501,1.06 [1:1.13],overlaps null,0.003842048188970577,0.001614333758882532,0.018507021941034554,471.4816746417017,159,1.0655401231569957e-32,0.05191116066520105,0.0015217612580789637,TRUE,0,188.01560847654528,0.065436208863487
ieu-b-110,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),LDL cholesterol,MR Egger,160,-0.02217213237354304,0.04694983320904726,0.6373988406251012,-0.11419380546327568,0.0698495407161896,0.9780718627292349,0.8920850481716778,1.0723468245804935,0.98 [0.89:1.07],overlaps null,0.003842048188970577,0.001614333758882532,0.018507021941034554,455.16430806906016,158,1.399175654316241e-30,0.05191116066520105,0.0015217612580789637,TRUE,0,188.01560847654528,0.065436208863487
ieu-b-110,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),LDL cholesterol,Weighted median,160,0.03009645239422538,0.03457380854481088,0.3840279767052459,-0.037668212353603944,0.09786111714205471,1.0305539285538037,0.9630324101470584,1.1028096131214324,1.03 [0.96:1.1],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-d-LDL_C,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),LDL cholesterol,Inverse variance weighted,48,0.022196315872443223,0.025183743275701536,0.37811501017510235,-0.027163820947931787,0.07155645269281824,1.022444486850723,0.9732017976235523,1.0741787892749153,1.02 [0.97:1.07],overlaps null,0.002247034394658018,0.0024947361977984313,0.37243403029872546,117.14088455650055,47,6.461458076047757e-8,0.05360897676452543,3.7029659078142936e-4,TRUE,0,214.88736959639002,0.082290553771505
met-d-LDL_C,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),LDL cholesterol,MR Egger,48,0.0014941506130714715,0.03413289305419798,0.9652736183547016,-0.06540631977315657,0.06839462099929951,1.0014952674122515,0.9366867916807076,1.0707877804590968,1 [0.94:1.07],overlaps null,0.002247034394658018,0.0024947361977984313,0.37243403029872546,115.11073433047953,46,7.540742578773727e-8,0.05360897676452543,3.7029659078142936e-4,TRUE,0,214.88736959639002,0.082290553771505
met-d-LDL_C,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),LDL cholesterol,Weighted median,48,0.0029763793490708355,0.0218029758060902,0.8914161212118231,-0.039757453230865956,0.04571021192900763,1.0029808131638993,0.9610225037900025,1.0467710252441038,1 [0.96:1.05],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ukb-d-30780_irnt,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),LDL direct,Inverse variance weighted,149,0.0303458350859131,0.021595072739788123,0.159955772711708,-0.011980507484071621,0.07267217765589783,1.030810962915064,0.9880909730532461,1.075377946205184,1.03 [0.99:1.08],overlaps null,0.003270801007638526,0.001255908454035593,0.010150516419665774,304.8844862960991,148,6.163456594538578e-13,0.053381085777467925,9.834171132897872e-4,TRUE,0,246.54980574186231,0.09235237655549855
ukb-d-30780_irnt,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),LDL direct,MR Egger,149,-0.016531645918809637,0.027799370957802664,0.5529736348847061,-0.07101841299610286,0.03795512115848358,0.9836042518378505,0.9314447412813022,1.0386846168701633,0.98 [0.93:1.04],overlaps null,0.003270801007638526,0.001255908454035593,0.010150516419665774,291.43763573843,147,1.3977715621049216e-11,0.053381085777467925,9.834171132897872e-4,TRUE,0,246.54980574186231,0.09235237655549855
ukb-d-30780_irnt,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),LDL direct,Weighted median,149,0.0052111919989598,0.024687976896698362,0.8328231447563614,-0.04317724271856899,0.05359962671648859,1.0052247938770535,0.9577416222936023,1.0550620989043702,1.01 [0.96:1.06],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-1845,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Mitogen-activated protein kinase 1,Wald ratio,1,-0.02475544020762627,0.016969454981034138,0.14461368473578445,-0.05801557197045318,0.00850469155520064,0.9755484627866914,0.9436352530621094,1.0085409591865224,0.98 [0.94:1.01],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-1845,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Mitogen-activated protein kinase 1,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-2142,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Ornithine decarboxylase,Wald ratio,1,0.04745166959578207,0.04510837727006444,0.29282338398947905,-0.04096074985354423,0.13586408904510838,1.0485955208512123,0.9598668041210755,1.1455261934556182,1.05 [0.96:1.15],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-2142,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Ornithine decarboxylase,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-1389,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Oxidoreductase HTATIP2,Inverse variance weighted,3,-0.017552309021870056,0.022305798450677417,0.4313436562325699,-0.06127167398519779,0.026167055941457677,0.9826008354321468,0.940567677293504,1.0265124191490447,0.98 [0.94:1.03],overlaps null,0.008826972267516248,0.014132694889149035,0.6445777932460109,1.8389040416419133,2,0.3987374810662957,0.04624310058353824,9.045894431023067e-6,TRUE,1.098304248491556e-34,52.75564648462403,0.04580454773166881
prot-a-1389,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Oxidoreductase HTATIP2,MR Egger,3,-0.05264212400285244,0.06176214001332911,0.5506426092685284,-0.17369591842897747,0.0684116704232726,0.9487194756641794,0.8405524553124141,1.0708060369295818,0.95 [0.84:1.07],overlaps null,0.008826972267516248,0.014132694889149035,0.6445777932460109,1.3228594231713484,1,0.2500795177191491,0.04624310058353824,9.045894431023067e-6,TRUE,1.098304248491556e-34,52.75564648462403,0.04580454773166881
prot-a-1389,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Oxidoreductase HTATIP2,Weighted median,3,-0.015882991554389096,0.024462282245169255,0.5161542156621256,-0.06382906475492084,0.03206308164614264,0.9842424780003827,0.938165351349708,1.0325826402634128,0.98 [0.94:1.03],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-1390,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Oxidoreductase HTATIP2,Wald ratio,1,-0.0014927601134497686,0.011344976862218241,0.8953173382917817,-0.023728914763397523,0.020743394536497983,0.9985083534987408,0.9765504022760266,1.0209600340986336,1 [0.98:1.02],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-1390,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Oxidoreductase HTATIP2,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ebi-a-GCST90010252,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Paraoxonase activity,Inverse variance weighted,5,-0.007012354209510283,0.012767067266569624,0.5828316105311875,-0.03203580605198675,0.01801109763296618,0.9930121749769989,0.968471904303011,1.0181742756515029,0.99 [0.97:1.02],overlaps null,0.043259329184425654,0.07636603022755964,0.6106820800797192,0.7600609500813289,4,0.943720825048552,0.2134132020851906,3.958979290370498e-6,TRUE,1.1756640344136838e-72,76.6847438138281,0.22561984675555835
ebi-a-GCST90010252,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Paraoxonase activity,MR Egger,5,-0.048941345475758916,0.07511058061262593,0.5611303229143779,-0.19615808347650576,0.09827539252498792,0.9522369810676103,0.8218822983970585,1.10326657464363,0.95 [0.82:1.1],overlaps null,0.043259329184425654,0.07636603022755964,0.6106820800797192,0.4391687719422319,3,0.9320374209778985,0.2134132020851906,3.958979290370498e-6,TRUE,1.1756640344136838e-72,76.6847438138281,0.22561984675555835
ebi-a-GCST90010252,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Paraoxonase activity,Weighted median,5,-0.010865940174768437,0.015490067292357305,0.48300480978696436,-0.041226472067788754,0.01949459171825188,0.9891928809115959,0.9596117800727826,1.019685852097363,0.99 [0.96:1.02],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-2416,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),26S proteasome non-ATPase regulatory subunit 1,Wald ratio,1,0.0868596881959911,0.05233853006681515,0.09700008819302544,-0.015723830734966596,0.1894432071269488,1.0907436247751179,0.9843991433068502,1.2085764835095059,1.09 [0.98:1.21],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-2416,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),26S proteasome non-ATPase regulatory subunit 1,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-2377,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Prolactin receptor,Inverse variance weighted,2,-0.023709043876771415,0.03553324000880636,0.5046216339601338,-0.09335419429403188,0.04593610654048905,0.9765698073911527,0.9108708179070807,1.047007511887685,0.98 [0.91:1.05],overlaps null,NA,NA,NA,1.4096221632246366,1,0.2351191264113931,0.025353899808831383,6.489669254571225e-6,TRUE,2.0279930759137228e-19,42.57197397607974,0.02516710765549828
prot-a-2539,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Transforming protein RhoA,Wald ratio,1,-0.020673557852617538,0.01417139046348783,0.14461368473578448,-0.048449483161053686,0.00710236745581861,0.9795386750916668,0.9527054657588035,1.0071276490852563,0.98 [0.95:1.01],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-2539,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Transforming protein RhoA,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ukb-b-998,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Soya dessert intake,Inverse variance weighted,4,-0.6276130464713888,0.8031685345658456,0.4345547138056465,-2.2018233742204463,0.9465972812776685,0.5338645913269776,0.11060130682120474,2.576926168996023,0.53 [0.11:2.58],overlaps null,0.017510652866922924,0.02491878228065442,0.5550156710914764,3.0663666449386144,3,0.3815055030240381,0.002008404963431262,2.048467789212143e-5,TRUE,1.2018371244004736e-19,32.66097614509072,0.002007662463691091
ukb-b-998,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Soya dessert intake,MR Egger,4,-1.7931729270789967,1.878082708423327,0.44044865478566175,-5.474215035588718,1.8878691814307242,0.16643125676835394,0.004193519021554037,6.605279023923183,0.17 [0:6.61],overlaps null,0.017510652866922924,0.02491878228065442,0.5550156710914764,2.45919215676945,2,0.2924106648183373,0.002008404963431262,2.048467789212143e-5,TRUE,1.2018371244004736e-19,32.66097614509072,0.002007662463691091
ukb-b-998,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Soya dessert intake,Weighted median,4,-0.03844961739838456,0.9885231946876721,0.9689732901951555,-1.975955078986222,1.8990558441894527,0.9622801856977473,0.13862884749674845,6.679584895259336,0.96 [0.14:6.68],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ukb-d-100920_2105,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Type milk consumed: soya with calcium,Wald ratio,1,-0.7994556897431536,1.0460962748766798,0.44473159652248445,-2.849804388501446,1.2508930090151384,0.4495736050553346,0.05785563699587325,3.493461257316493,0.45 [0.06:3.49],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ukb-d-100920_2105,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Type milk consumed: soya with calcium,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ukb-d-1418_4,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Milk type used: Soya,Wald ratio,1,0.32100410082738806,2.6884093444293753,0.904956096468146,-4.948278214254188,5.590286415908963,1.3785112339187857,0.007095615547152856,267.8123144372995,1.38 [0.01:267.81],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ukb-d-1418_4,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Milk type used: Soya,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-3029,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Tumor necrosis factor,Wald ratio,1,-0.04692737430167598,0.04618249534450651,0.309567945539029,-0.13744506517690874,0.04359031657355678,0.9541566913701074,0.8715822288975903,1.0445543306199314,0.95 [0.87:1.04],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-3029,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Tumor necrosis factor,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-3198,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Vascular endothelial growth factor A,Wald ratio,1,0.021671826625386997,0.017146939747558942,0.20626991040631296,-0.011936175279828529,0.05527982853060252,1.0219083663186752,0.988134778275058,1.056836306252761,1.02 [0.99:1.06],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-3198,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Vascular endothelial growth factor A,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-d-VLDL_C,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),VLDL cholesterol,Inverse variance weighted,57,0.0033854873007352266,0.029393482179137793,0.908303906356949,-0.05422573777037484,0.0609967123718453,1.003391224535485,0.9472182594280839,1.0628954197765434,1 [0.95:1.06],overlaps null,0.005423262134814119,0.00309070303285418,0.0848797653916953,152.9321022331179,56,6.202250675001528e-11,0.06766187322927247,4.889463308346855e-4,TRUE,0,139.53199836234333,0.06573579648786847
met-d-VLDL_C,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),VLDL cholesterol,MR Egger,57,-0.07305003582645693,0.052254752366068836,0.1677379042104165,-0.17546935046395185,0.029369278811037985,0.9295543178436347,0.8390631136745117,1.0298048093637622,0.93 [0.84:1.03],overlaps null,0.005423262134814119,0.00309070303285418,0.0848797653916953,144.82461400232853,55,5.13168805732582e-10,0.06766187322927247,4.889463308346855e-4,TRUE,0,139.53199836234333,0.06573579648786847
met-d-VLDL_C,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),VLDL cholesterol,Weighted median,57,-0.010576688943648233,0.03122815153278066,0.7348426402048817,-0.07178386594789832,0.05063048806060186,0.9894790475552466,0.930732036960266,1.0519341192427822,0.99 [0.93:1.05],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ieu-b-4872,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Oestradiol,Wald ratio,1,-0.03885702073507769,0.15057095534842604,0.7963571162577392,-0.3339760932179927,0.25626205174783734,0.9618882293868362,0.7160709009735119,1.292091278356761,0.96 [0.72:1.29],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ieu-b-4872,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Oestradiol,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-2146,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Oxidized low-density lipoprotein receptor 1,Wald ratio,1,-0.053347280334728034,0.04445606694560669,0.23013934044341655,-0.14048117154811715,0.03378661087866108,0.9480507159365308,0.8689400255742138,1.0343638611811241,0.95 [0.87:1.03],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-2146,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Oxidized low-density lipoprotein receptor 1,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ebi-a-GCST90012031,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Myeloperoxidase levels,Inverse variance weighted,10,-0.0143935182868317,0.03897557830184577,0.7119072382280951,-0.09078565175844941,0.061998615184786006,0.9857095731884575,0.9132134356159767,1.0639608713378117,0.99 [0.91:1.06],overlaps null,0.006771578911730664,0.007540494276639688,0.3953929895089675,23.563585864599865,9,0.005047300038482288,0.04088243800707527,7.581945531268678e-5,TRUE,1.5908077855494068e-168,92.25123099243628,0.04069396365092959
ebi-a-GCST90012031,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Myeloperoxidase levels,MR Egger,10,-0.06942106643563589,0.07285069314760596,0.3685299101888148,-0.21220842500494358,0.0733662921336718,0.9329337702661098,0.8087961066653004,1.0761246407224818,0.93 [0.81:1.08],overlaps null,0.006771578911730664,0.007540494276639688,0.3953929895089675,21.40573955891701,8,0.006144250929008233,0.04088243800707527,7.581945531268678e-5,TRUE,1.5908077855494068e-168,92.25123099243628,0.04069396365092959
ebi-a-GCST90012031,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Myeloperoxidase levels,Weighted median,10,-0.03506426446026294,0.0327521354565595,0.28435168250085185,-0.09925844995511955,0.029129921034593678,0.965543364140558,0.9055086491088709,1.029558347071931,0.97 [0.91:1.03],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-2866,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),"Steroidogenic acute regulatory protein, mitochondrial",Inverse variance weighted,2,0.008318911673209877,0.026667370250193608,0.755077795225673,-0.04394913401716959,0.06058695736358934,1.0083536099695385,0.9570026351146246,1.0624599822724794,1.01 [0.96:1.06],overlaps null,NA,NA,NA,0.2377473502211361,1,0.6258378521357801,0.027935326216218304,1.0807151768730365e-6,TRUE,1.1655301370768518e-21,47.1853022912526,0.027818483173691826
ebi-a-GCST90010172,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),"Superoxide dismutase [Mn],mitochondrial levels",Wald ratio,1,0.0422315784052429,0.04042901103428741,0.2962143587496556,-0.03700928322196041,0.12147244003244621,1.043136018557611,0.9636671893711148,1.1291582459317056,1.04 [0.96:1.13],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ebi-a-GCST90010172,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),"Superoxide dismutase [Mn],mitochondrial levels",NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-2799,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),"Superoxide dismutase [Mn], mitochondrial",Wald ratio,1,-0.006011707008384749,0.011390602752728999,0.5976535826328673,-0.028337288403733587,0.01631387438696409,0.9940063271454124,0.9720604467861174,1.0164476722325817,0.99 [0.97:1.02],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-2799,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),"Superoxide dismutase [Mn], mitochondrial",NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ieu-b-4864,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Total Testosterone,Inverse variance weighted,108,0.13132547355822258,0.03853322542409108,6.541450255046451e-4,0.055800351727004066,0.2068505953894411,1.1403388710687088,1.057386557261748,1.229798820440612,1.14 [1.06:1.23],positive,-0.003427197372778268,0.0024504654462667035,0.16485484584988427,320.1962459687305,107,4.0128454706689675e-23,0.0397183613375478,0.001113414200357355,TRUE,0,81.14004209294677,0.04208526101576542
ieu-b-4864,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Total Testosterone,MR Egger,108,0.22011738642083498,0.07417697385116954,0.003711978940765453,0.07473051767254268,0.36550425516912727,1.246223011660408,1.0775937192897704,1.4412405779569215,1.25 [1.08:1.44],positive,-0.003427197372778268,0.0024504654462667035,0.16485484584988427,314.3946123845814,106,1.6256745544661055e-22,0.0397183613375478,0.001113414200357355,TRUE,0,81.14004209294677,0.04208526101576542
ieu-b-4864,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Total Testosterone,Weighted median,108,0.12295438737350742,0.042154691309210755,0.0035370744298653164,0.040331192407454336,0.2055775823395605,1.1308328395151817,1.0411555399071395,1.2282342665535093,1.13 [1.04:1.23],positive,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ieu-b-4869,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Bioavailable Testosterone,Inverse variance weighted,115,0.11185675990687362,0.034732068222743495,0.0012793976229923698,0.04378190619029637,0.17993161362345086,1.1183526562328447,1.0447544755560323,1.1971354925638518,1.12 [1.04:1.2],positive,-0.003744945287366953,0.0025270951588714768,0.14114570859719064,308.96234604950325,114,6.728814191187658e-20,0.04712689445718851,0.0010822023937115432,TRUE,0,76.61265357465494,0.04775459504347954
ieu-b-4869,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Bioavailable Testosterone,MR Egger,115,0.20641935975855683,0.07256469253814168,0.005279890686182396,0.06419256238379914,0.3486461571333145,1.2292686017032413,1.0662977078219276,1.417147654026278,1.23 [1.07:1.42],positive,-0.003744945287366953,0.0025270951588714768,0.14114570859719064,303.07234158872797,113,2.6673712871801052e-19,0.04712689445718851,0.0010822023937115432,TRUE,0,76.61265357465494,0.04775459504347954
ieu-b-4869,ieu-a-1126,Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Bioavailable Testosterone,Weighted median,115,0.12071173315794953,0.038307489702968454,0.0016264221790105232,0.045629053340131356,0.19579441297576772,1.1282996141165986,1.0466860742321173,1.2162768288950663,1.13 [1.05:1.22],positive,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-70,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),RAC-alpha/beta/gamma serine/threonine-protein kinase,Wald ratio,1,-0.022477522477522476,0.025224775224775224,0.3728813672634215,-0.07191808191808191,0.026963036963036962,0.9777732148657486,0.9306071262396387,1.0273298288312414,0.98 [0.93:1.03],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-70,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),RAC-alpha/beta/gamma serine/threonine-protein kinase,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-71,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),RAC-alpha/beta/gamma serine/threonine-protein kinase,Wald ratio,1,-0.024379129642287535,0.023012075643654588,0.2894149453712948,-0.069482797903850535,0.020724538619275458,0.9759156410624372,0.9328761806722876,1.0209407831422408,0.98 [0.93:1.02],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-71,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),RAC-alpha/beta/gamma serine/threonine-protein kinase,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-d-ApoA1,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Apolipoprotein A1,Inverse variance weighted,66,0.0342539321738298,0.03102976076848142,0.2696340125859006,-0.026564398932393783,0.09507226328005339,1.0348473544049477,0.9737853310805372,1.0997383229531825,1.03 [0.97:1.1],overlaps null,-0.0012667816298667196,0.0029523283399755205,0.6693067897243599,137.7380891093179,65,3.7934767972111553e-7,0.07270161006941549,6.787312137268314e-4,TRUE,0,142.4871698433583,0.07875396556859365
met-d-ApoA1,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Apolipoprotein A1,MR Egger,66,0.05236024732937666,0.05249538809552033,0.3223142425279746,-0.050530713337843196,0.1552512079965965,1.0537552866722155,0.9507247282941327,1.1679513229681244,1.05 [0.95:1.17],overlaps null,-0.0012667816298667196,0.0029523283399755205,0.6693067897243599,137.3429948294625,64,2.8414587451951255e-7,0.07270161006941549,6.787312137268314e-4,TRUE,0,142.4871698433583,0.07875396556859365
met-d-ApoA1,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Apolipoprotein A1,Weighted median,66,0.05342752213026648,0.034773391890959196,0.12442844538503561,-0.014728325976013534,0.1215833702365465,1.054880533502967,0.9853796052850319,1.1292835106340795,1.05 [0.99:1.13],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ieu-a-1,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Adiponectin,Inverse variance weighted,11,-0.04495183536282018,0.048373966190003274,0.3527560353160904,-0.1397648090952266,0.04986113836958624,0.956043528213852,0.8695627245948184,1.0511251252927003,0.96 [0.87:1.05],overlaps null,-0.00949960844905101,0.004623479597569417,0.07008502068752243,15.129065464774634,10,0.12742673576476773,0.07718011210014392,7.143480375862288e-5,TRUE,0,105.43260097901171,0.02826559025561699
ieu-a-1,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Adiponectin,MR Egger,11,0.04755946062796921,0.0616210771669164,0.4600143667170906,-0.07321785061918692,0.16833677187512536,1.0487085561367373,0.929398337966686,1.183335057517417,1.05 [0.93:1.18],overlaps null,-0.00949960844905101,0.004623479597569417,0.07008502068752243,10.298446917640272,9,0.3268689664683519,0.07718011210014392,7.143480375862288e-5,TRUE,0,105.43260097901171,0.02826559025561699
ieu-a-1,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Adiponectin,Weighted median,11,-0.0069439068466224186,0.045786497228787686,0.8794563706554043,-0.09668544141504629,0.08279762772180144,0.9930801463678963,0.9078415305710554,1.0863219448549928,0.99 [0.91:1.09],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-c-841,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Albumin,Inverse variance weighted,3,0.19098308082189594,0.07609812529651747,0.012083549585600647,0.04183075524072172,0.34013540640307016,1.2104389722754934,1.0427179892611362,1.405137842343698,1.21 [1.04:1.41],positive,0.0538204807451156,0.05790555868933844,0.523266585113968,0.9516586031062335,2,0.6213695400106768,0.012291569836283354,4.031845639566888e-5,TRUE,6.642218960888824e-43,80.2916172020224,0.01254760753862574
met-c-841,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Albumin,MR Egger,3,-0.021013171184412253,0.24044684254854842,0.944505408422763,-0.49228898257956716,0.45026264021074264,0.9792060671808344,0.6112257067265084,1.5687241414288053,0.98 [0.61:1.57],overlaps null,0.0538204807451156,0.05790555868933844,0.523266585113968,0.08777618923285739,1,0.7670235384613452,0.012291569836283354,4.031845639566888e-5,TRUE,6.642218960888824e-43,80.2916172020224,0.01254760753862574
met-c-841,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Albumin,Weighted median,3,0.1649746347339689,0.08594477562688589,0.05491573472219007,-0.003477125494727451,0.33342639496266524,1.1793632034705848,0.9965289127055714,1.395742309095799,1.18 [1:1.4],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-d-Albumin,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Albumin,Inverse variance weighted,26,-0.007429360579152766,0.09287421839138171,0.9362421962329863,-0.18946282862626093,0.17460410746795538,0.9925981689024854,0.8274034720495396,1.1907747044716008,0.99 [0.83:1.19],overlaps null,0.009382853458749433,0.0073749854884556975,0.21547202012823502,147.72674471973022,25,2.210646636901667e-19,0.022756214719991875,6.848403175326887e-4,TRUE,2.7275471100523296e-241,99.05661207573866,0.022722006668076614
met-d-Albumin,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Albumin,MR Egger,26,-0.15077456750403315,0.14529943639850565,0.30976066164326344,-0.4355614628451042,0.1340123278370379,0.8600415581223559,0.6469013540194576,1.143406915291882,0.86 [0.65:1.14],overlaps null,0.009382853458749433,0.0073749854884556975,0.21547202012823502,138.39311092901616,24,4.5911782795006084e-18,0.022756214719991875,6.848403175326887e-4,TRUE,2.7275471100523296e-241,99.05661207573866,0.022722006668076614
met-d-Albumin,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Albumin,Weighted median,26,-0.0706832383978334,0.057320097412824435,0.21752657214689386,-0.18303062932696929,0.041664152531302484,0.931756990224305,0.8327426489995884,1.0425442840892432,0.93 [0.83:1.04],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ukb-d-30600_irnt,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Albumin,Inverse variance weighted,186,-0.050074497570170004,0.049092591184988404,0.30772793364909745,-0.14629597629274727,0.04614698115240727,0.9511585628594573,0.8639019708385279,1.0472283224712846,0.95 [0.86:1.05],overlaps null,8.404219196864765e-4,0.002508339858273944,0.7379682336099933,681.0141565389927,185,6.795117348897343e-58,0.043053563306594586,0.003122811955370593,TRUE,0,85.0763839756563,0.043073613998040196
ukb-d-30600_irnt,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Albumin,MR Egger,186,-0.0773917307178075,0.09523180934358288,0.4174593356905827,-0.26404607703122995,0.10926261559561495,0.9255272251405232,0.7679381545311627,1.1154552478243303,0.93 [0.77:1.12],overlaps null,8.404219196864765e-4,0.002508339858273944,0.7379682336099933,680.5989201398829,184,4.0995019335211945e-58,0.043053563306594586,0.003122811955370593,TRUE,0,85.0763839756563,0.043073613998040196
ukb-d-30600_irnt,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Albumin,Weighted median,186,-0.007067119503110871,0.048328230225231646,0.8837384776414906,-0.10179045074456489,0.08765621173834315,0.9929577938627997,0.9032188006668658,1.0916127738538206,0.99 [0.9:1.09],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ieu-b-107,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),apolipoprotein A-I,Inverse variance weighted,264,0.07039917935727466,0.02956047988637251,0.017240871031085504,0.012460638779984538,0.12833771993456478,1.0729363898410096,1.0125385960018067,1.1369369041246942,1.07 [1.01:1.14],positive,-5.941220686207788e-4,0.0013986237726433554,0.6713380538295628,611.726781303788,263,7.896344164242548e-30,0.08914914276657057,0.003024558517545092,TRUE,0,171.47077817020093,0.10540777721348657
ieu-b-107,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),apolipoprotein A-I,MR Egger,264,0.08608130458412389,0.04732274090223984,0.0700489083058881,-0.0066712675842661995,0.17883387675251397,1.0898949381575718,0.9933509359187169,1.1958220738201404,1.09 [0.99:1.2],overlaps null,-5.941220686207788e-4,0.0013986237726433554,0.6713380538295628,611.3057574014185,262,5.8134508524990755e-30,0.08914914276657057,0.003024558517545092,TRUE,0,171.47077817020093,0.10540777721348657
ieu-b-107,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),apolipoprotein A-I,Weighted median,264,0.03955200379288674,0.03511528101531693,0.2600185220146539,-0.029273946997134447,0.10837795458290791,1.0403445993433063,0.9711503842907938,1.1144688844181148,1.04 [0.97:1.11],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-c-842,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Apolipoprotein A-I,Inverse variance weighted,11,0.04441297919994067,0.029835038255504476,0.13658795165962467,-0.014063695780848103,0.10288965418072946,1.0454139999894072,0.9860347360101193,1.1083690984316765,1.05 [0.99:1.11],overlaps null,0.007153935424118943,0.010400139069479864,0.5088735109998417,14.362670192835338,10,0.15708245646880684,0.03881354605696007,8.015055387692018e-5,TRUE,2.630206532057852e-148,77.0017658406783,0.03935594553423642
met-c-842,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Apolipoprotein A-I,MR Egger,11,-0.0065603868238028615,0.08019307432450712,0.9365903253270091,-0.16373881249983682,0.1506180388522311,0.9934610855325222,0.8489637316398336,1.1625525233699499,0.99 [0.85:1.16],overlaps null,0.007153935424118943,0.010400139069479864,0.5088735109998417,13.645285892986783,9,0.13551435958821267,0.03881354605696007,8.015055387692018e-5,TRUE,2.630206532057852e-148,77.0017658406783,0.03935594553423642
met-c-842,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Apolipoprotein A-I,Weighted median,11,0.052888167701349395,0.03236647361992792,0.10225009415232342,-0.010550120593709328,0.11632645599640812,1.0543117324217237,0.9895053367300677,1.1233625407169767,1.05 [0.99:1.12],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ukb-d-30630_irnt,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Apoliprotein A,Inverse variance weighted,222,0.06319645921853051,0.02739742218786507,0.02107394197562036,0.009497511730314975,0.11689540670674604,1.0652360941262085,1.0095427562180954,1.1240018604859572,1.07 [1.01:1.12],positive,-0.0018070674528232304,0.00144945363859609,0.2138247520687979,535.1628341127074,221,4.408400905676735e-28,0.07527540442709078,0.002619034053995093,TRUE,0,171.6448063278531,0.09703784729333688
ukb-d-30630_irnt,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Apoliprotein A,MR Egger,222,0.10174964393238489,0.04129177334064131,0.014499842292389821,0.020817768184727928,0.18268151968004187,1.1071062662580933,1.0210359694448257,1.2004320332166014,1.11 [1.02:1.2],positive,-0.0018070674528232304,0.00144945363859609,0.2138247520687979,531.4083886934443,220,8.579669257263045e-28,0.07527540442709078,0.002619034053995093,TRUE,0,171.6448063278531,0.09703784729333688
ukb-d-30630_irnt,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Apoliprotein A,Weighted median,222,0.07165983808613263,0.031208432920709083,0.021666216862920404,0.01049130956154283,0.13282836661072245,1.0742898494124333,1.0105465363143842,1.1420539669155279,1.07 [1.01:1.14],positive,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-132,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Apolipoprotein E (isoform E2),Wald ratio,1,-0.1011326860841424,0.043284789644012944,0.01946787361496609,-0.18597087378640775,-0.016294498381877034,0.9038131015081919,0.8302977780601792,0.9838375388241141,0.9 [0.83:0.98],negative,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-132,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Apolipoprotein E (isoform E2),NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-131,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Apolipoprotein E (isoform E3),Wald ratio,1,0.0060967160870167665,0.019398642095053348,0.7533040472859123,-0.0319246224192878,0.044118054593321326,1.006115338887279,0.9685795885137481,1.0451057271375652,1.01 [0.97:1.05],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-131,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Apolipoprotein E (isoform E3),NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-127,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Apolipoprotein B,Wald ratio,1,0.010316529894490035,0.032825322391559206,0.7533040472859123,-0.05402110199296601,0.07465416178194609,1.01036992876138,0.9474121140070926,1.0775114418028582,1.01 [0.95:1.08],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-127,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Apolipoprotein B,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-c-843,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Apolipoprotein B,Inverse variance weighted,20,-0.010211957604102758,0.027806304707212744,0.7134300732592007,-0.06471231483023973,0.04428839962203422,0.9898400073963953,0.9373370825705442,1.045283770866664,0.99 [0.94:1.05],overlaps null,0.0028630951758074675,0.006828071509768523,0.6799494803044753,41.37653003933241,19,0.002149638216608611,0.06876637281847174,1.870562685502808e-4,TRUE,2.627575404357855e-263,74.89558402093132,0.07071718421634327
met-c-843,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Apolipoprotein B,MR Egger,20,-0.027298523586063217,0.04968634116833276,0.5894713492850099,-0.12468375227599543,0.070086705103869,0.973070713602858,0.8827760343565463,1.0726011772190267,0.97 [0.88:1.07],overlaps null,0.0028630951758074675,0.006828071509768523,0.6799494803044753,40.97627626778613,18,0.0015338976064214734,0.06876637281847174,1.870562685502808e-4,TRUE,2.627575404357855e-263,74.89558402093132,0.07071718421634327
met-c-843,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Apolipoprotein B,Weighted median,20,0.003962218867963329,0.027004375584783146,0.8833490306394786,-0.048966357278211636,0.056890795014138296,1.003970078834683,0.9522131642022044,1.0585402062150848,1 [0.95:1.06],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ieu-b-108,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),apolipoprotein B,Inverse variance weighted,177,0.011325699936816003,0.029670302855507973,0.7026702654271286,-0.04682809365997962,0.06947949353361163,1.0113900784908472,0.9542514253612534,1.0719500790711172,1.01 [0.95:1.07],overlaps null,0.0019441993701980757,0.001578400635898522,0.21969401619576454,430.5498771875286,176,2.3796449319380125e-23,0.06145698502892919,0.0019865972364298506,TRUE,0,240.59553912341835,0.08978558558416183
ieu-b-108,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),apolipoprotein B,MR Egger,177,-0.022593085479848347,0.04044791952620577,0.5771676813389051,-0.10187100775121166,0.05668483679151496,0.97766022698618,0.9031460429945464,1.0583222136050932,0.98 [0.9:1.06],overlaps null,0.0019441993701980757,0.001578400635898522,0.21969401619576454,426.84918038432096,175,4.576339556294142e-23,0.06145698502892919,0.0019865972364298506,TRUE,0,240.59553912341835,0.08978558558416183
ieu-b-108,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),apolipoprotein B,Weighted median,177,0.013811313554904676,0.03280002650310537,0.673699372558757,-0.05047673839118185,0.0780993655009912,1.0139071303564213,0.9507760449955276,1.0812300903021055,1.01 [0.95:1.08],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-d-ApoB,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Apolipoprotein B,Inverse variance weighted,52,0.011088795104915951,0.02782711624582014,0.6902698874877825,-0.04345235273689153,0.06562994294672343,1.0111505036736532,0.9574781742186088,1.0678314854684565,1.01 [0.96:1.07],overlaps null,0.0037465286349141597,0.0027882242214061696,0.1851127270918302,107.02714710965682,51,7.44541711423566e-6,0.060914987589111055,4.753793047108725e-4,TRUE,0,188.4836080671642,0.08129412305145553
met-d-ApoB,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Apolipoprotein B,MR Egger,52,-0.02819356629291563,0.04021151908831905,0.4864713444790715,-0.10700814370602096,0.05062101112018971,0.9722001634053153,0.8985183556911674,1.0519241501730547,0.97 [0.9:1.05],overlaps null,0.0037465286349141597,0.0027882242214061696,0.1851127270918302,103.29704587573517,50,1.4106403697264956e-5,0.060914987589111055,4.753793047108725e-4,TRUE,0,188.4836080671642,0.08129412305145553
met-d-ApoB,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Apolipoprotein B,Weighted median,52,0.0068473844822229315,0.027100896804702762,0.8005289103031719,-0.04627037325499448,0.05996514221944035,1.0068708814195848,0.9547837792911891,1.0617995339251225,1.01 [0.95:1.06],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-275,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Basigin,Wald ratio,1,0.033557046979865765,0.048528652555498195,0.4892580638494894,-0.06155911202891069,0.12867320598864224,1.0341264358335653,0.9402973612117872,1.1373183945891814,1.03 [0.94:1.14],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-275,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Basigin,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ieu-b-35,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),C-Reactive protein level,Inverse variance weighted,53,0.043765310709706816,0.04252920677974848,0.30344921414481113,-0.03959193457860021,0.12712255599801384,1.0447371374972794,0.9611815841046434,1.1355561784745771,1.04 [0.96:1.14],overlaps null,-7.311530191263294e-4,0.003414206877275476,0.83128386390787945,199.12853412679212,52,4.419976779460504e-19,0.03172797569493132,8.752657233038044e-4,TRUE,0,166.0407128758088,0.04128657678290181
ieu-b-35,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),C-Reactive protein level,MR Egger,53,0.053894426221872016,0.06387291192602541,0.4027350566408652,-0.0712964811531378,0.17908533359688183,1.0553731765397898,0.9311857721659151,1.196122809274658,1.06 [0.93:1.2],overlaps null,-7.311530191263294e-4,0.003414206877275476,0.83128386390787945,198.94963432523883,51,2.366331201977969e-19,0.03172797569493132,8.752657233038044e-4,TRUE,0,166.0407128758088,0.04128657678290181
ieu-b-35,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),C-Reactive protein level,Weighted median,53,0.06186862156824981,0.03204480921056374,0.053521288822096905,-9.392044844551278e-4,0.12467644762095474,1.0638225722054906,0.9990612364300296,1.1327818794950986,1.06 [1:1.13],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-670,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),C-reactive protein,Inverse variance weighted,3,0.06808708328432635,0.025609651997690424,0.007845458172661189,0.017892165368853116,0.11828200119979958,1.0704585234639403,1.0180531890803308,1.1255614763033586,1.07 [1.02:1.13],positive,-0.0824895016659927,0.0713978516280692,0.45419393512979284,1.77817907048188,2,0.41102981060073657,0.04378392349385333,4.244684464055592e-5,TRUE,1.0928203505408895e-31,49.93279320192895,0.043460151453047685
prot-a-670,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),C-reactive protein,MR Egger,3,0.5025071383004491,0.3768784669729627,0.409663999602167,-0.2361746569665577,1.241188933567456,1.6528600289964557,0.7896427452814982,3.459724402939025,1.65 [0.79:3.46],overlaps null,-0.0824895016659927,0.0713978516280692,0.45419393512979284,0.4433456490413794,1,0.5055120576973736,0.04378392349385333,4.244684464055592e-5,TRUE,1.0928203505408895e-31,49.93279320192895,0.043460151453047685
prot-a-670,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),C-reactive protein,Weighted median,3,0.06409950053342559,0.03283427981526191,0.050912948021974755,-2.55687904487753e-4,0.12845468897133894,1.0661984808013851,0.9997443447808787,1.1370698983171923,1.07 [1:1.14],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ukb-d-30710_irnt,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),C-reactive protein,Inverse variance weighted,180,0.052707820384739486,0.03156126272906785,0.09491615636564117,-0.009152254564233492,0.11456789533371246,1.0541216072747066,0.9908894998381705,1.1213887755444825,1.05 [0.99:1.12],overlaps null,-2.9540409988595176e-4,0.0016288972826407353,0.8562974769225077,506.05763884990023,179,5.4283987660805035e-33,0.050299345618834895,0.002425639623033144,TRUE,0,174.79561264571916,0.08221071287530522
ukb-d-30710_irnt,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),C-reactive protein,MR Egger,180,0.05853092466045751,0.045083654060154334,0.1958728848434332,-0.029833037297444985,0.14689488661836,1.0602777739177613,0.9706075752845585,1.158232210926665,1.06 [0.97:1.16],overlaps null,-2.9540409988595176e-4,0.0016288972826407353,0.8562974769225077,505.96415310649536,178,3.304847781402218e-33,0.050299345618834895,0.002425639623033144,TRUE,0,174.79561264571916,0.08221071287530522
ukb-d-30710_irnt,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),C-reactive protein,Weighted median,180,0.07076671533084962,0.031023976574726,0.02254649235248146,0.009959721244386661,0.13157370941731258,1.0733308050380805,1.0100094843396614,1.1406219792053642,1.07 [1.01:1.14],positive,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-b-51,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),cathepsin D,Inverse variance weighted,2,0.02230537582422156,0.020055557473422136,0.2660610672375771,-0.017003516823685824,0.06161426847212895,1.0225560006778909,0.9831402270979928,1.0635520200498747,1.02 [0.98:1.06],overlaps null,NA,NA,NA,0.3895601248915514,1,0.5325307093951698,0.04491915770494122,6.775420180777618e-6,TRUE,1.44378478652326e-34,79.95059209061124,0.04503115572282335
prot-a-495,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cyclin-dependent kinase inhibitor 1B,Wald ratio,1,-0.01918512658227848,0.01997626582278481,0.3368559305746708,-0.058338607594936705,0.019968354430379746,0.980997736673251,0.9433304744886706,1.0201690556850542,0.98 [0.94:1.02],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-495,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cyclin-dependent kinase inhibitor 1B,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-2218,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),"Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A",Wald ratio,1,0.07933461292386436,0.05566218809980806,0.1540741534670207,-0.029763275751759438,0.18843250159948816,1.0825665022144404,0.9706752887311344,1.207355585665295,1.08 [0.97:1.21],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-2218,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),"Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A",NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-346,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Calcium/calmodulin-dependent protein kinase type 1,Inverse variance weighted,3,-0.017707581441697214,0.007729771343069135,0.02197332748856303,-0.03285793327411272,-0.0025572296092817096,0.9824482764671114,0.9676760243887184,0.997446037317002,0.98 [0.97:1],negative,-0.02667998819907273,0.046702789058833925,0.6695765419167519,0.6515018151063606,2,0.72198500604678,0.2905704839534254,2.5417997780357724e-5,TRUE,1.5516713053152402e-253,962.121209780234,0.46679506533379456
prot-a-346,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Calcium/calmodulin-dependent protein kinase type 1,MR Egger,3,0.009130334985583443,0.04761090514431428,0.8793799370447872,-0.08418703909727254,0.10244770906843942,1.0091721436395238,0.9192593025844965,1.10787936835089,1.01 [0.92:1.11],overlaps null,-0.02667998819907273,0.046702789058833925,0.6695765419167519,0.325150300900582,1,0.5685288183225632,0.2905704839534254,2.5417997780357724e-5,TRUE,1.5516713053152402e-253,962.121209780234,0.46679506533379456
prot-a-346,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Calcium/calmodulin-dependent protein kinase type 1,Weighted median,3,-0.01765383536920533,0.00795193708754179,0.02641420064292299,-0.03323963206078724,-0.0020680386776234204,0.9825010806223932,0.9673067341076248,0.997934098241032,0.98 [0.97:1],negative,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-347,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Calcium/calmodulin-dependent protein kinase type 1D,Inverse variance weighted,3,-0.04814423785261007,0.026943448401921498,0.07395971305584041,-0.1009533967203762,0.004664921015156059,0.9529963190210935,0.9039751601113827,1.0046758186982157,0.95 [0.9:1],overlaps null,-0.01915820585366646,0.027200892787701873,0.6093566063760343,3.7563431822095024,2,0.15286935807949517,0.0728296371905048,4.188783519217343e-5,TRUE,2.3637952396100823e-53,84.64450553078537,0.07151176314786167
prot-a-347,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Calcium/calmodulin-dependent protein kinase type 1D,MR Egger,3,0.02060550118363449,0.10246174515821507,0.8736582256083181,-0.18021951932646704,0.22143052169373603,1.0208192602025072,0.8350868735808797,1.2478605459716494,1.02 [0.84:1.25],overlaps null,-0.01915820585366646,0.027200892787701873,0.6093566063760343,2.510806355622433,1,0.11306806378505498,0.0728296371905048,4.188783519217343e-5,TRUE,2.3637952396100823e-53,84.64450553078537,0.07151176314786167
prot-a-347,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Calcium/calmodulin-dependent protein kinase type 1D,Weighted median,3,-0.06385661173618909,0.022651126550366073,0.0048153075142774475,-0.10825281977490658,-0.01946040369747159,0.9381395080823015,0.8974006871083459,0.9807277276116515,0.94 [0.9:0.98],negative,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-348,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Calcium/calmodulin-dependent protein kinase type II subunit alpha,Wald ratio,1,-0.01893327176171785,0.023089355806972987,0.4122161071716261,-0.0641884091433849,0.026321865619949203,0.9812448367975638,0.9378282874598849,1.0266713455079726,0.98 [0.94:1.03],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-348,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Calcium/calmodulin-dependent protein kinase type II subunit alpha,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-349,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Calcium/calmodulin-dependent protein kinase type II subunit beta,Wald ratio,1,-0.014946619217081849,0.01779359430604982,0.40090838652089933,-0.049822064056939494,0.0199288256227758,0.9851645270532279,0.9513986974648551,1.0201287304157387,0.99 [0.95:1.02],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-349,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Calcium/calmodulin-dependent protein kinase type II subunit beta,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-c-875,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cholesterol esters in large HDL,Inverse variance weighted,13,0.06846478915589038,0.02661314074471286,0.010093972773187356,0.016303033296253176,0.12062654501552758,1.0708629182998628,1.0164366528908952,1.1282035004623068,1.07 [1.02:1.13],positive,0.004335673264197201,0.010312073433711799,0.6822556455707984,20.739754104614534,12,0.05432370680732986,0.0648910965646224,1.6853692271190965e-4,TRUE,2.811566963300008e-233,104.94930175813884,0.06615518445625727
met-c-875,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cholesterol esters in large HDL,MR Egger,13,0.04106966310523201,0.07075233873847045,0.5732964036373247,-0.09760492082217008,0.17974424703263409,1.0419246867264302,0.9070071726250218,1.1969112103800146,1.04 [0.91:1.2],overlaps null,0.004335673264197201,0.010312073433711799,0.6822556455707984,20.411728164020335,11,0.040003742925653916,0.0648910965646224,1.6853692271190965e-4,TRUE,2.811566963300008e-233,104.94930175813884,0.06615518445625727
met-c-875,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cholesterol esters in large HDL,Weighted median,13,0.05987485394973017,0.027152046104078047,0.027442228363637317,0.006656843585737197,0.11309286431372315,1.061703670210175,1.0066790496156761,1.1197359116275414,1.06 [1.01:1.12],positive,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-c-881,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cholesterol esters in large VLDL,Inverse variance weighted,25,0.009871002765215986,0.02351401299305947,0.6746371541180656,-0.03621646270118058,0.055958468231612546,1.0099198818090218,0.964431507437539,1.0575537607466692,1.01 [0.96:1.06],overlaps null,0.0019081504242071943,0.005350209347227472,0.7246052458499461,55.56496212759966,24,2.625696923036163e-4,0.10270486471872796,2.53330620084643e-4,TRUE,0,90.95343554997712,0.105657415004876
met-c-881,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cholesterol esters in large VLDL,MR Egger,25,-2.514337382016557e-4,0.03713911560734808,0.994656700889611,-0.0730441003286039,0.07254123285220057,0.9997485978686116,0.9295598352276668,1.0752371402702217,1 [0.93:1.08],overlaps null,0.0019081504242071943,0.005350209347227472,0.7246052458499461,55.259356286718045,23,1.7947777462228585e-4,0.10270486471872796,2.53330620084643e-4,TRUE,0,90.95343554997712,0.105657415004876
met-c-881,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cholesterol esters in large VLDL,Weighted median,25,0.005820582717913185,0.02268667601951817,0.7975154241461582,-0.03864530228034243,0.0502864677161688,1.00583755522348,0.962091900436089,1.051572294745822,1.01 [0.96:1.05],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-c-887,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cholesterol esters in large VLDL,Inverse variance weighted,12,-0.12180690324873716,0.025032526101641757,1.1391101034892839e-6,-0.170870654407955,-0.07274315208951931,0.885319304280011,0.8429305957776543,0.9298396267224694,0.89 [0.84:0.93],negative,-0.0010479321001567515,0.007138805503633032,0.8862120451026464,3.8628541231082787,11,0.9737583467259494,0.04154318433727714,1.2167667676605435e-4,TRUE,1.7051187970776087e-144,69.97993272180987,0.04244046154729363
met-c-887,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cholesterol esters in large VLDL,MR Egger,12,-0.11346174110286883,0.062116833394283165,0.09771968676570765,-0.23521073455566383,0.008287252349926166,0.8927383509425573,0.7904042665850366,1.0083216866819535,0.89 [0.79:1.01],overlaps null,-0.0010479321001567515,0.007138805503633032,0.8862120451026464,3.841305715200386,10,0.9542220892176624,0.04154318433727714,1.2167667676605435e-4,TRUE,1.7051187970776087e-144,69.97993272180987,0.04244046154729363
met-c-887,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cholesterol esters in large VLDL,Weighted median,12,-0.12181783705758127,0.03137990519690174,1.0358668623170394e-4,-0.18332245124350868,-0.06031322287165387,0.885309624420891,0.8324996718985191,0.9414695975853793,0.89 [0.83:0.94],negative,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-c-899,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cholesterol esters in medium HDL,Inverse variance weighted,7,0.09406092407238796,0.06574861797527659,0.1525407388711793,-0.03480636715915415,0.2229282153039301,1.0986266766894834,0.9657924072806698,1.2497308589660687,1.1 [0.97:1.25],overlaps null,0.0020974331843819447,0.021495023044329334,0.9260585171135216,20.10904712632882,6,0.002648289095097658,0.02069469750326165,1.161001811753868e-4,TRUE,7.33916650536493e-70,59.17815405770613,0.02104994549606213
met-c-899,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cholesterol esters in medium HDL,MR Egger,7,0.07600256262041492,0.19856297656010094,0.7176268798052093,-0.3131808714373829,0.46518599667821275,1.0789653391323462,0.7311176623066176,1.592310325777287,1.08 [0.73:1.59],overlaps null,0.0020974331843819447,0.021495023044329334,0.9260585171135216,20.07082668512716,5,0.0012120545858083675,0.02069469750326165,1.161001811753868e-4,TRUE,7.33916650536493e-70,59.17815405770613,0.02104994549606213
met-c-899,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cholesterol esters in medium HDL,Weighted median,7,0.08156843721360288,0.04559038375811461,0.07358924150057941,-0.0077887149523017535,0.17092558937950753,1.0849874685623482,0.9922415384918973,1.1864024647935514,1.08 [0.99:1.19],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-c-905,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cholesterol esters in medium LDL,Inverse variance weighted,24,-0.006715681766817264,0.021516662863673822,0.7549528256936495,-0.04888834097961795,0.035456977445983424,0.9933068180286491,0.952287455246666,1.0360930717990302,0.99 [0.95:1.04],overlaps null,-0.0013543711173253116,0.00524907662279737,0.7987891873278249,41.93176462211726,23,0.009246063707984342,0.0973209153939637,1.9864304655577852e-4,TRUE,0,89.28137176236022,0.10017192616269002
met-c-905,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cholesterol esters in medium LDL,MR Egger,24,2.8235995254985533e-4,0.034902055835586664,0.9936180451003338,-0.0681256694852,0.06869038939029971,1.0002823998198735,0.9341430729214508,1.0711045324783344,1 [0.93:1.07],overlaps null,-0.0013543711173253116,0.00524907662279737,0.7987891873278249,41.80525669022081,22,0.006599091182312034,0.0973209153939637,1.9864304655577852e-4,TRUE,0,89.28137176236022,0.10017192616269002
met-c-905,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cholesterol esters in medium LDL,Weighted median,24,0.0048420039804491916,0.0220353522581092,0.8260752171309345,-0.038347286445444835,0.04803129440634322,1.0048537454247801,0.9623786617846347,1.0492034890110342,1 [0.96:1.05],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-c-910,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cholesterol esters in medium VLDL,Inverse variance weighted,14,-0.09025613778546021,0.023578736898204875,1.2926148534344383e-4,-0.13647046210594177,-0.04404181346497866,0.9136971229387532,0.8724320896856711,0.9569139447488009,0.91 [0.87:0.96],negative,0.006119162404616156,0.0076692494876643685,0.4404425328957968,14.299466600394467,13,0.3530972620028298,0.053537526627753025,1.3338356049591787e-4,TRUE,1.2060316220277167e-191,79.86292168778593,0.05487222537626808
met-c-910,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cholesterol esters in medium VLDL,MR Egger,14,-0.1384213307646015,0.06493094906284139,0.05437790516777437,-0.2656859909277706,-0.011156670601432384,0.8707317483756554,0.7666798341304208,0.9889053342445834,0.87 [0.77:0.99],negative,0.006119162404616156,0.0076692494876643685,0.4404425328957968,13.579077318799705,12,0.3283908024846842,0.053537526627753025,1.3338356049591787e-4,TRUE,1.2060316220277167e-191,79.86292168778593,0.05487222537626808
met-c-910,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cholesterol esters in medium VLDL,Weighted median,14,-0.11452464895177962,0.0303369399776494,1.5995053387177295e-4,-0.17398505130797243,-0.0550642465955868,0.8917899564595759,0.8403094590918545,0.9464243414582805,0.89 [0.84:0.95],negative,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-c-943,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cholesterol esters in very large HDL,Inverse variance weighted,13,0.08400242876274537,0.028729338640337828,0.003456481219508584,0.02769292502768323,0.14031193249780752,1.087631535404572,1.0280799383264434,1.15063266260419,1.09 [1.03:1.15],positive,-0.008782223279148094,0.009608553112384332,0.38031472495749663,19.045442228993213,12,0.08743768176305786,0.04891839391555753,1.738676499227121e-4,TRUE,2.9659097173714473e-171,76.47810438266569,0.04908926012245622
met-c-943,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cholesterol esters in very large HDL,MR Egger,13,0.1488052497573152,0.07657474563618466,0.07800656035748973,-0.001281251689606716,0.29889175120423717,1.1604469698721342,0.9987195687628999,1.3483636568305943,1.16 [1:1.35],overlaps null,-0.008782223279148094,0.009608553112384332,0.38031472495749663,17.701126790157126,11,0.08877965773834563,0.04891839391555753,1.738676499227121e-4,TRUE,2.9659097173714473e-171,76.47810438266569,0.04908926012245622
met-c-943,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cholesterol esters in very large HDL,Weighted median,13,0.05561455536830733,0.03254878285267526,0.08751535941824354,-0.008181059022936178,0.11941016975955085,1.0571901169391873,0.991852314767436,1.1268320159296632,1.06 [0.99:1.13],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-d-Total_CE,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Total esterified cholesterol,Inverse variance weighted,61,0.02899634340574028,0.027448054518967854,0.29078186879001605,-0.024801843451436715,0.08279453026291728,1.0294208302939498,0.9755031952238128,1.086318580022645,1.03 [0.98:1.09],overlaps null,-9.164591136299151e-5,0.002631934632671769,0.9723402231455573,106.91447573917429,60,1.8673335031102023e-4,0.05865853344309517,4.942852991512063e-4,TRUE,0,154.31493160788077,0.07565113340698283
met-d-Total_CE,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Total esterified cholesterol,MR Egger,61,0.03009360220330247,0.04194202123416995,0.47589396850118604,-0.05211275941567063,0.11229996382227557,1.0305509912825368,0.9492218271095674,1.1188484243639605,1.03 [0.95:1.12],overlaps null,-9.164591136299151e-5,0.002631934632671769,0.9723402231455573,106.91227863036586,59,1.3571834077618974e-4,0.05865853344309517,4.942852991512063e-4,TRUE,0,154.31493160788077,0.07565113340698283
met-d-Total_CE,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Total esterified cholesterol,Weighted median,61,0.010651428698975897,0.03063716957472742,0.7280928355076932,-0.04939742366748985,0.07070028106544164,1.010708357109072,0.9518027855682611,1.0732595014630346,1.01 [0.95:1.07],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-879,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Dynactin-associated protein,Inverse variance weighted,2,0.057255747469597426,0.07406629529214648,0.4395023952816414,-0.08791419130300966,0.20242568624220453,1.0589265935647627,0.9158394603424428,1.2243690942726966,1.06 [0.92:1.22],overlaps null,NA,NA,NA,4.535110135831448,1,0.03320631999448288,0.03155056072184482,3.1957722255713074e-5,TRUE,4.471430660455581e-23,53.17767634385489,0.031240966840827333
prot-a-908,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Epidermal growth factor,Wald ratio,1,-0.0640542577241899,0.029766390354182368,0.031405330982836224,-0.12239638281838734,-0.00571213262999247,0.9379541068948479,0.88479758042540535,0.9943041505808928,0.94 [0.88:0.99],negative,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-908,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Epidermal growth factor,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-928,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),ELAV-like protein 1,Wald ratio,1,-0.02125124131082423,0.02005958291956306,0.2894149453712948,-0.06056802383316783,0.01806554121151937,0.978972975215855,0.9412297407858476,1.0182297102116744,0.98 [0.94:1.02],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-928,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),ELAV-like protein 1,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-905,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Ephrin-B2,Wald ratio,1,-0.07364576993304929,0.0660377358490566,0.26476156715979793,-0.2030797321972002,0.055788192331101646,0.9290007155488221,0.816213160362457,1.0573737001581438,0.93 [0.82:1.06],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-905,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Ephrin-B2,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-962,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Ephrin type-B receptor 2,Wald ratio,1,4.921259842519685e-4,0.033710629921259845,0.9883524639241112,-0.06558070866141733,0.06656496062992126,1.000492247098111,0.9365234581546478,1.0688303937157073,1 [0.94:1.07],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-962,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Ephrin type-B receptor 2,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-1320,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Histone deacetylase 8,Wald ratio,1,0.008986340762041696,0.0492451473759885,0.8552046738584231,-0.08753414809489576,0.10550682961897914,1.0090268391420358,0.916187585056095,1.1112736940728472,1.01 [0.92:1.11],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-1320,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Histone deacetylase 8,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-1397,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Intercellular adhesion molecule 1,Inverse variance weighted,3,1.5284633198588035e-4,0.021024827109821433,0.994199588247321,-0.041055814803264125,0.04136150746723589,1.0001528580135817,0.9597755587687901,1.0422288109481952,1 [0.96:1.04],overlaps null,-0.0416396999227006,0.02841499459211384,0.3812187443374941,21.069673368628006,2,2.659368744829252e-5,0.2805055300831925,9.179630818661092e-5,TRUE,7.521447817723905e-239,3130.476198109417,0.7401569488696367
prot-a-1397,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Intercellular adhesion molecule 1,MR Egger,3,0.0408202065497706,0.03241967268910826,0.427298117227755,-0.02272235192088158,0.10436276502042278,1.041664804199077,0.9775338564960055,1.1100030521669562,1.04 [0.98:1.11],overlaps null,-0.0416396999227006,0.02841499459211384,0.3812187443374941,6.6942362219690805,1,0.00967250968507406,0.2805055300831925,9.179630818661092e-5,TRUE,7.521447817723905e-239,3130.476198109417,0.7401569488696367
prot-a-1397,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Intercellular adhesion molecule 1,Weighted median,3,0.003513724318748551,0.006640095291996526,0.5966890829471453,-0.00950086245356464,0.016528311091061742,1.0035199046846233,0.9905441281442178,1.016665659292681,1 [0.99:1.02],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-1426,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Interferon alpha/beta receptor 1,Wald ratio,1,0.02243700379703141,0.03969623748705557,0.5719259089376576,-0.05536762167759751,0.10024162927166033,1.0226906065100967,0.9461372634444334,1.10543799198478,1.02 [0.95:1.11],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-1426,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Interferon alpha/beta receptor 1,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-1443,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Insulin-like growth factor I,Inverse variance weighted,3,-0.014786029106332236,0.027813088669678167,0.5949883404710052,-0.06929968289890144,0.03972762468623697,0.9853227474377084,0.9330470199398676,1.0405273216356916,0.99 [0.93:1.04],overlaps null,-0.016799543176693774,0.012188686375813903,0.3995807293141805,2.09673534106563,2,0.3505094292689568,0.03721010842626091,1.0466882117206023e-5,TRUE,8.250531343156331e-28,42.21179732044945,0.03698857426777589
prot-a-1443,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Insulin-like growth factor I,MR Egger,3,0.06361215510429209,0.06303411734851924,0.4970943660472553,-0.05993471489880561,0.1871590251073898,1.0656790004386894,0.941826018784137,1.205819025303755,1.07 [0.94:1.21],overlaps null,-0.016799543176693774,0.012188686375813903,0.3995807293141805,0.19705232640228965,1,0.6571107178003703,0.03721010842626091,1.0466882117206023e-5,TRUE,8.250531343156331e-28,42.21179732044945,0.03698857426777589
prot-a-1443,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Insulin-like growth factor I,Weighted median,3,-0.012217097611911518,0.0333503822772555,0.7141221557449475,-0.0775838468753323,0.05314965165150927,0.9878572281355742,0.9253494334852164,1.0545874540650384,0.99 [0.93:1.05],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ukb-d-30770_irnt,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),IGF-1,Inverse variance weighted,318,0.0643324419795887,0.029595265793603536,0.029724593413392654,0.006325721024125777,0.12233916293505163,1.0664468715465265,1.0063457706511842,1.1301373374833643,1.07 [1.01:1.13],positive,-9.799896012914191e-4,0.0016098850365566131,0.5431389896509025,779.329557670714,317,7.24388766744406e-41,0.08356626327904101,0.003599156904696576,TRUE,0,105.22406103870784,0.08753534522247032
ukb-d-30770_irnt,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),IGF-1,MR Egger,318,0.09542017552910087,0.05904004104782696,0.10705018426745276,-0.020298304924639965,0.2111386559828417,1.1001210019519803,0.9799063188229414,1.2350835949191499,1.1 [0.98:1.24],overlaps null,-9.799896012914191e-4,0.0016098850365566131,0.5431389896509025,778.4167520653054,316,6.04406614022516e-41,0.08356626327904101,0.003599156904696576,TRUE,0,105.22406103870784,0.08753534522247032
ukb-d-30770_irnt,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),IGF-1,Weighted median,318,0.07324052062209913,0.038556158943961125,0.05748821730257196,-0.0023295509080646787,0.14881059215226294,1.075989303410745,0.9976731603898744,1.1604531694547233,1.08 [1:1.16],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-1444,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Insulin-like growth factor 1 receptor,Wald ratio,1,-0.1932078935291418,0.042680128499311604,5.986042193028805e-6,-0.27686094538779255,-0.10955484167049107,0.8243105874874957,0.7581599154139169,0.8962330120987925,0.82 [0.76:0.9],negative,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-1444,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Insulin-like growth factor 1 receptor,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ebi-a-GCST90010149,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Lipoprotein lipase levels,Inverse variance weighted,3,-0.0015849838960062905,0.01626289246095765,0.9223609813060428,-0.03346025311948329,0.030290285327470707,0.998416271527606,0.9670933494113065,1.0307537032054706,1 [0.97:1.03],overlaps null,0.02622184577267257,0.019418880317098836,0.4058023412763245,1.8333393273400724,2,0.39984845599588165,0.11081870455960946,8.106985170981472e-6,TRUE,7.032636485945663e-35,56.923663453025846,0.11634716279363165
ebi-a-GCST90010149,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Lipoprotein lipase levels,MR Egger,3,-0.07914616655622786,0.059696710780747064,0.41139726962032275,-0.1961517196864921,0.03785938657403638,0.9239048705819332,0.8218875287000637,1.0385851835896733,0.92 [0.82:1.04],overlaps null,0.02622184577267257,0.019418880317098836,0.4058023412763245,0.009955295337452283,1,0.9205219825016735,0.11081870455960946,8.106985170981472e-6,TRUE,7.032636485945663e-35,56.923663453025846,0.11634716279363165
ebi-a-GCST90010149,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Lipoprotein lipase levels,Weighted median,3,-0.002346816737926101,0.0179320929323871,0.8958762176444851,-0.03749371888540482,0.032800085409552614,0.9976559348835367,0.9632004676743371,1.0333439380605296,1 [0.96:1.03],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ukb-d-30790_irnt,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Lipoprotein A,Inverse variance weighted,20,0.002968020490014542,0.009193615392153121,0.7468202324918353,-0.015051465678605574,0.020987506658634657,1.0029724294236853,0.9850612414532071,1.0212092932415253,1 [0.99:1.02],overlaps null,-0.008257598659200841,0.004928287410972693,0.11110985019375996,20.506544779963757,19,0.36469542807084454,0.034547544453679586,9.45845557912806e-5,TRUE,0,7039.240290698945,0.28047139457405407
ukb-d-30790_irnt,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Lipoprotein A,MR Egger,20,0.013554494464776457,0.010873484998412153,0.22853638748741886,-0.007757536132111362,0.03486652506166428,1.0136467730835186,0.9922724758947047,1.0354814887475137,1.01 [0.99:1.04],overlaps null,-0.008257598659200841,0.004928287410972693,0.11110985019375996,17.699072429978738,18,0.47563615674958043,0.034547544453679586,9.45845557912806e-5,TRUE,0,7039.240290698945,0.28047139457405407
ukb-d-30790_irnt,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Lipoprotein A,Weighted median,20,0.012402062124961194,0.009828366454254691,0.20699771633025071,-0.006861536125377999,0.031665660375300386,1.0124792866148606,0.9931619504648911,1.0321723514924122,1.01 [0.99:1.03],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ieu-b-110,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),LDL cholesterol,Inverse variance weighted,160,0.06016919238127732,0.03542578074170379,0.08942139757656574,-0.009265337872462108,0.12960372263501674,1.0620162163981535,0.9907774531108665,1.138377180820284,1.06 [0.99:1.14],overlaps null,0.004459966328413732,0.0017887607619407845,0.013685288168475158,409.4108103488134,159,5.334017264014046e-24,0.05191116066520105,0.0018863564537779367,TRUE,0,188.01560847654528,0.065436208863487
ieu-b-110,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),LDL cholesterol,MR Egger,160,-0.03587321430548178,0.05195085754904925,0.4908790702483873,-0.1376968951016183,0.06595046649065474,0.96476260382612955,0.8713627660453255,1.0681738054583778,0.96 [0.87:1.07],overlaps null,0.004459966328413732,0.0017887607619407845,0.013685288168475158,393.91191756933773,158,3.859700633392349e-22,0.05191116066520105,0.0018863564537779367,TRUE,0,188.01560847654528,0.065436208863487
ieu-b-110,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),LDL cholesterol,Weighted median,160,0.02386019643647167,0.038051067624596695,0.5306217323206776,-0.050719896107737854,0.09844028898068119,1.0241471284635222,0.9505448845688301,1.1034485143916712,1.02 [0.95:1.1],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-d-LDL_C,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),LDL cholesterol,Inverse variance weighted,48,0.014451846971578594,0.02705638043318642,0.5932459062551951,-0.038578658677466786,0.06748235262062398,1.0145567797936936,0.962156019843182,1.0698113800640305,1.01 [0.96:1.07],overlaps null,0.002803922133884087,0.002672155908529201,0.29951693587902517,94.84013938624376,47,4.481113937235383e-5,0.05360897676452543,4.262490165250134e-4,TRUE,0,214.88736959639002,0.082290553771505
met-d-LDL_C,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),LDL cholesterol,MR Egger,48,-0.011406123102101973,0.03657520138056008,0.7565606304273553,-0.08309351780799973,0.06028127160379579,0.988658680101556,0.9202650820226237,1.0621352530206307,0.99 [0.92:1.06],overlaps null,0.002803922133884087,0.002672155908529201,0.29951693587902517,92.62311803533257,46,5.5906645812065395e-5,0.05360897676452543,4.262490165250134e-4,TRUE,0,214.88736959639002,0.082290553771505
met-d-LDL_C,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),LDL cholesterol,Weighted median,48,0.00743028473350302,0.026061255818023543,0.775561042273268,-0.04364977666982313,0.058510346136829164,1.007457957796232,0.9572891637699653,1.0602559551910375,1.01 [0.96:1.06],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ukb-d-30780_irnt,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),LDL direct,Inverse variance weighted,149,0.02268205288123918,0.024943356549600063,0.3631693912561718,-0.026206925955976942,0.0715710317184553,1.0229412466149597,0.9741334952471625,1.0741944498691807,1.02 [0.97:1.07],overlaps null,0.003220685130855045,0.0014600900421938617,0.028949576598243022,286.0414433941668,148,7.669793950585584e-11,0.053381085777467925,0.0013023025120200702,TRUE,0,246.54980574186231,0.09235237655549855
ukb-d-30780_irnt,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),LDL direct,MR Egger,149,-0.023550537275187935,0.03233623615275637,0.46758747435909453,-0.08692956013459041,0.039828485584214535,0.9767246124210168,0.9167416685186187,1.040632275448501,0.98 [0.92:1.04],overlaps null,0.003220685130855045,0.0014600900421938617,0.028949576598243022,276.8769854735235,147,5.193683349334073e-10,0.053381085777467925,0.0013023025120200702,TRUE,0,246.54980574186231,0.09235237655549855
ukb-d-30780_irnt,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),LDL direct,Weighted median,149,0.008859575271326846,0.0283864456240909,0.7549600933413148,-0.04677785815189132,0.06449700869454501,1.008898937466558,0.954299363870548,1.0666223876465102,1.01 [0.95:1.07],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-1845,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Mitogen-activated protein kinase 1,Wald ratio,1,-0.021361549211419445,0.02016370533040527,0.2894149453712948,-0.06088241165901377,0.01815931323617488,0.9788649927179903,0.9409338761245811,1.0183251961500503,0.98 [0.94:1.02],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-1845,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Mitogen-activated protein kinase 1,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-2142,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Ornithine decarboxylase,Wald ratio,1,0.05682483889865261,0.05330990041007616,0.2864534482437003,-0.047662565905096654,0.16131224370240188,1.0584703913173825,0.9534554611831222,1.1750518140672694,1.06 [0.95:1.18],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-2142,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Ornithine decarboxylase,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-1389,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Oxidoreductase HTATIP2,Inverse variance weighted,3,0.002355939528481497,0.03500715391729299,0.9463438304025574,-0.06625808214941277,0.07096996120637576,1.002358716934718,0.9358892967995005,1.0735489772678317,1 [0.94:1.07],overlaps null,0.01822354432381491,0.02016239562362615,0.5321279880124901,3.5154938356665433,2,0.17243293204824117,0.04624310058353824,1.6795665669395437e-5,TRUE,3.2698540680799303e-34,52.75564648462403,0.04580454773166881
prot-a-1389,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Oxidoreductase HTATIP2,MR Egger,3,-0.06990280749751636,0.08797974109858524,0.5725744376051638,-0.24234310005074344,0.10253748505571071,0.9324844459986222,0.784786870939673,1.107978833779698,0.93 [0.78:1.11],overlaps null,0.01822354432381491,0.02016239562362615,0.5321279880124901,1.9348605958320375,1,0.16422765083573257,0.04624310058353824,1.6795665669395437e-5,TRUE,3.2698540680799303e-34,52.75564648462403,0.04580454773166881
prot-a-1389,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Oxidoreductase HTATIP2,Weighted median,3,-0.005932064682630266,0.030500404019114954,0.8457911699267491,-0.06571285656009557,0.05384872719483504,0.994085495273646,0.9363997067245156,1.0553249481144653,0.99 [0.94:1.06],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-1390,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Oxidoreductase HTATIP2,Wald ratio,1,-0.0056724884311091205,0.013584117032392894,0.6762524541466515,-0.03229735781459919,0.02095238095238095,0.9943435697537546,0.9682186318927664,1.0211734231738518,0.99 [0.97:1.02],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-1390,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Oxidoreductase HTATIP2,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ebi-a-GCST90010252,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Paraoxonase activity,Inverse variance weighted,5,-0.004229635769536804,0.015166743324442547,0.7803402374256552,-0.03395645268544419,0.025497181146370586,0.9957792965419224,0.9666135971473611,1.0258250146158034,1 [0.97:1.03],overlaps null,-0.0029831467861185495,0.09010188410580104,0.9756676266289411,0.30937542142679336,4,0.9892009493368448,0.2134132020851906,2.2960245576621635e-6,TRUE,1.1451959333800236e-72,76.6847438138281,0.22561984675555835
ebi-a-GCST90010252,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Paraoxonase activity,MR Egger,5,-0.0013351291021601376,0.0887304685541816,0.9889394142089745,-0.17524684746835606,0.1725765892640358,0.9986657617861718,0.8392498285023321,1.1883628329644438,1 [0.84:1.19],overlaps null,-0.0029831467861185495,0.09010188410580104,0.9756676266289411,0.30827924236647475,3,0.9584639319122853,0.2134132020851906,2.2960245576621635e-6,TRUE,1.1451959333800236e-72,76.6847438138281,0.22561984675555835
ebi-a-GCST90010252,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Paraoxonase activity,Weighted median,5,-0.004487230341245982,0.017430628370877218,0.7968440264767817,-0.03865126194816533,0.029676801265673364,0.9955228222351257,0.962086166705033,1.0301215461658764,1 [0.96:1.03],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-2416,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),26S proteasome non-ATPase regulatory subunit 1,Wald ratio,1,0.06533036377134374,0.06273199703043801,0.2976806093897265,-0.05762435040831476,0.18828507795100224,1.0675116333055112,0.9440044957430409,1.2071776060193633,1.07 [0.94:1.21],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-2416,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),26S proteasome non-ATPase regulatory subunit 1,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-2377,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Prolactin receptor,Inverse variance weighted,2,-0.07251012349284221,0.06702064732794721,0.2792937480186418,-0.20387059225561877,0.05885034526993434,0.9300563311940081,0.8155679051616853,1.0606165025860999,0.93 [0.82:1.06],overlaps null,NA,NA,NA,3.5586582699619274,1,0.059235601084244124,0.025353899808831383,3.3268787889185745e-5,TRUE,1.2617986184532326e-18,42.57197397607974,0.02516710765549828
prot-a-2539,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Transforming protein RhoA,Wald ratio,1,-0.017839279759919974,0.016838946315438478,0.2894149453712948,-0.05084361453817939,0.015165055018339445,0.9823188982009968,0.9504272919219858,1.01528062794942,0.98 [0.95:1.02],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-2539,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Transforming protein RhoA,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ukb-b-998,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Soya dessert intake,Inverse variance weighted,4,-0.7536969529143767,0.940786704072426,0.42305362100250593,-2.597638892896332,1.0902449870675783,0.4706234598886091,0.07444915328167324,2.9750028205095433,0.47 [0.07:2.98],overlaps null,0.023503908043893892,0.026666894772688354,0.47107793066127246,1.4233116581534488,3,0.7000795620996817,0.002008404963431262,1.3839788660190711e-5,TRUE,3.4403098181285294e-19,32.66097614509072,0.002007662463691091
ukb-b-998,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Soya dessert intake,MR Egger,4,-2.299831900785405,1.990554341681521,0.36732369041941026,-6.201318410481186,1.6016546089103758,0.10027569857229351,0.002026756776683582,4.961234539753212,0.1 [0:4.96],overlaps null,0.023503908043893892,0.026666894772688354,0.47107793066127246,0.646465067210693,2,0.7238055256891783,0.002008404963431262,1.3839788660190711e-5,TRUE,3.4403098181285294e-19,32.66097614509072,0.002007662463691091
ukb-b-998,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Soya dessert intake,Weighted median,4,-0.9364301096582515,1.15989426189024,0.41947009018554676,-3.209822862963122,1.3369626436466189,0.3920248259632019,0.0403637625561074,3.807461307846412,0.39 [0.04:3.81],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ukb-d-100920_2105,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Type milk consumed: soya with calcium,Wald ratio,1,-0.10205817315870046,1.2417077734308557,0.9344942092863027,-2.5358054090831774,2.331689062765777,0.9029770211154053,0.07919790685708337,10.295316290793181,0.9 [0.08:10.3],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ukb-d-100920_2105,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Type milk consumed: soya with calcium,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ukb-d-1418_4,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Milk type used: Soya,Wald ratio,1,2.367405243601987,3.1699154956704576,0.4551628982600077,-3.8456291279121104,8.580439615116084,10.669671137404505,0.021372951010497437,5326.446597124036,10.67 [0.02:5326.45],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ukb-d-1418_4,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Milk type used: Soya,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-3029,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Tumor necrosis factor,Wald ratio,1,-0.08603351955307262,0.055121042830540035,0.11856839591318126,-0.19407076350093108,0.022003724394785845,0.917563474387099,0.823599621413875,1.022247591716949,0.92 [0.82:1.02],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-3029,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Tumor necrosis factor,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-3198,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Vascular endothelial growth factor A,Wald ratio,1,0.004763038818766373,0.020481066920695404,0.8161045358884769,-0.035379852345796624,0.044905929983329367,1.004774400119104,0.9652386984288103,1.0459294646785904,1 [0.97:1.05],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-3198,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Vascular endothelial growth factor A,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-d-VLDL_C,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),VLDL cholesterol,Inverse variance weighted,57,-0.009276613725104778,0.03299586414313878,0.7785993850362385,-0.07394850744565679,0.05539527999544722,0.9907662813132895,0.9287195147501491,1.0569583265959972,0.99 [0.93:1.06],overlaps null,0.008709167101392934,0.0033698638646806264,0.012438239088554843,135.8838907212927,56,1.3722969611875764e-8,0.06766187322927247,6.379144385937444e-4,TRUE,0,139.53199836234333,0.06573579648786847
met-d-VLDL_C,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),VLDL cholesterol,MR Egger,57,-0.1320075065009428,0.056953048959673076,0.024205364068222532,-0.24363548246190203,-0.02037953053998358,0.8763344168495573,0.7837732813049496,0.9798267285616437,0.88 [0.78:0.98],negative,0.008709167101392934,0.0033698638646806264,0.012438239088554843,121.16899013734759,55,6.960460331991684e-7,0.06766187322927247,6.379144385937444e-4,TRUE,0,139.53199836234333,0.06573579648786847
met-d-VLDL_C,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),VLDL cholesterol,Weighted median,57,-0.02397316680666676,0.03402059900225895,0.4810179796734294,-0.09065354085109428,0.04270720723776077,0.9763119069725836,0.913334089041206,1.0436322821335522,0.98 [0.91:1.04],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ieu-b-4872,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Oestradiol,Wald ratio,1,-0.026714201755365912,0.1797137208997343,0.8818308833528701,-0.37895309471884514,0.3255246912081133,0.9736394662147295,0.6845777222237517,1.3847570252381975,0.97 [0.68:1.38],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ieu-b-4872,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Oestradiol,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-2146,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Oxidized low-density lipoprotein receptor 1,Wald ratio,1,-0.043933054393305436,0.05230125523012552,0.40090838652089933,-0.14644351464435146,0.05857740585774058,0.9570180234807534,0.8637745215678616,1.0603270580435293,0.96 [0.86:1.06],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-2146,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Oxidized low-density lipoprotein receptor 1,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ebi-a-GCST90012031,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Myeloperoxidase levels,Inverse variance weighted,10,-0.03542076777589005,0.038904707654574086,0.3625855549654008,-0.11167399477885526,0.04083245922707515,0.96519920608025,0.8943357681106455,1.0416775674599743,0.97 [0.89:1.04],overlaps null,0.008071110442449288,0.0073651194360198815,0.30503196874210275,16.608802011633717,9,0.05520635412494334,0.04088243800707527,8.187209208981996e-5,TRUE,1.1312950795183478e-163,92.25123099243628,0.04069396365092959
ebi-a-GCST90012031,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Myeloperoxidase levels,MR Egger,10,-0.1005693142110768,0.07081539294277477,0.19333652986113758,-0.23936748437891536,0.038228855956761745,0.9043224278446848,0.7871255728653086,1.0389689799124913,0.9 [0.79:1.04],overlaps null,0.008071110442449288,0.0073651194360198815,0.30503196874210275,14.441023182979848,8,0.07097016572586047,0.04088243800707527,8.187209208981996e-5,TRUE,1.1312950795183478e-163,92.25123099243628,0.04069396365092959
ebi-a-GCST90012031,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Myeloperoxidase levels,Weighted median,10,-0.043724927268492884,0.03952142783104509,0.26857072736908577,-0.12118692581734125,0.03373707128035549,0.9572172256193394,0.8858683524493941,1.0343126204801718,0.96 [0.89:1.03],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-2866,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),"Steroidogenic acute regulatory protein, mitochondrial",Inverse variance weighted,2,0.010005940309247967,0.03176752267257884,0.7527814755609701,-0.05225840412900656,0.0722702847475025,1.0100561671123376,0.9490835880358054,1.0749458462695252,1.01 [0.95:1.07],overlaps null,NA,NA,NA,0.007860278532758802,1,0.9293535437937902,0.027935326216218304,4.806860357348722e-7,TRUE,1.175947349629971e-21,47.1853022912526,0.027818483173691826
ebi-a-GCST90010172,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),"Superoxide dismutase [Mn],mitochondrial levels",Wald ratio,1,0.05420577594087579,0.04763928051810937,0.2551882019419415,-0.039167213874618564,0.14757876575637013,1.0557018178402828,0.9615899045286295,1.1590245726816444,1.06 [0.96:1.16],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ebi-a-GCST90010172,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),"Superoxide dismutase [Mn],mitochondrial levels",NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-2799,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),"Superoxide dismutase [Mn], mitochondrial",Wald ratio,1,0,0.013605442176870748,1,-0.026666666666666665,0.026666666666666665,1,0.973685749353145,1.0270254038988826,1 [0.97:1.03],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-2799,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),"Superoxide dismutase [Mn], mitochondrial",NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ieu-b-4864,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Total Testosterone,Inverse variance weighted,108,0.17340934911357903,0.04557190560871707,1.4170053502957002e-4,0.08408841412049356,0.2627302841066645,1.1893528659910884,1.0877250598120494,1.3004759126222953,1.19 [1.09:1.3],positive,-0.004878798148717029,0.002884735627844245,0.09372799326402621,314.5447597331896,107,2.681360211075816e-22,0.0397183613375478,0.0016163218816578407,TRUE,0,81.14004209294677,0.04208526101576542
ieu-b-4864,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Total Testosterone,MR Egger,108,0.29978235042692375,0.0873192947642835,8.521317135121105e-4,0.12863653268892808,0.47092816816491945,1.3495650433528095,1.137276686135624,1.6014799462992522,1.35 [1.14:1.6],positive,-0.004878798148717029,0.002884735627844245,0.09372799326402621,306.28007032921414,106,2.4441053735757562e-21,0.0397183613375478,0.0016163218816578407,TRUE,0,81.14004209294677,0.04208526101576542
ieu-b-4864,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Total Testosterone,Weighted median,108,0.20048728683905875,0.050958725329899014,8.343696563717769e-5,0.10060818519245669,0.30036638848566083,1.2219980766830723,1.105843271100007,1.3503534709143088,1.22 [1.11:1.35],positive,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ieu-b-4869,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Bioavailable Testosterone,Inverse variance weighted,115,0.15942808118094653,0.03828516300107345,3.124101912918753e-5,0.08438916169884257,0.23446700066305048,1.1728399099262452,1.0880522396865087,1.2642347528388245,1.17 [1.09:1.26],positive,-0.004196104605483422,0.002782336566394721,0.13431398342755882,263.51854460288047,114,7.410695325192381e-14,0.04712689445718851,0.0014182512748874253,TRUE,0,76.61265357465494,0.04775459504347954
ieu-b-4869,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Bioavailable Testosterone,MR Egger,115,0.2653114949654313,0.07986750644432301,0.0012049421750806334,0.10877118233455824,0.4218518075963044,1.3038370512070534,1.1149072106871973,1.5247825467488705,1.3 [1.11:1.52],positive,-0.004196104605483422,0.002782336566394721,0.13431398342755882,258.3191656541699,113,2.1731947261810803e-13,0.04712689445718851,0.0014182512748874253,TRUE,0,76.61265357465494,0.04775459504347954
ieu-b-4869,ieu-a-1127,ER+ Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Bioavailable Testosterone,Weighted median,115,0.20258292862816465,0.04556378832992774,8.742745873405054e-6,0.1132779035015063,0.291887953754823,1.224561632127535,1.1199431258219423,1.3389529845797394,1.22 [1.12:1.34],positive,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-70,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),RAC-alpha/beta/gamma serine/threonine-protein kinase,Wald ratio,1,-0.025224775224775224,0.03896103896103896,0.5173498692965586,-0.10158841158841159,0.05113886113886113,0.9750907111600161,0.9034013046670305,1.0524690301847484,0.98 [0.9:1.05],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-70,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),RAC-alpha/beta/gamma serine/threonine-protein kinase,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-71,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),RAC-alpha/beta/gamma serine/threonine-protein kinase,Wald ratio,1,-0.030986557302346774,0.035771246297562086,0.38635744446607045,-0.10109820004556845,0.03912508544087491,0.9694886055306324,0.9038442709791269,1.0399005519341686,0.97 [0.9:1.04],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-71,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),RAC-alpha/beta/gamma serine/threonine-protein kinase,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-d-ApoA1,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Apolipoprotein A1,Inverse variance weighted,66,0.04206035981676138,0.04333067934094345,0.3317060909303996,-0.04286777169148779,0.12698849132501056,1.0429574295702329,0.9580380614444303,1.135403950711244,1.04 [0.96:1.14],overlaps null,0.0014797321366194721,0.004128520397929018,0.7212108006504361,115.06714696640411,65,1.29500609162741e-4,0.07270161006941549,0.001365271873199428,TRUE,0,142.4871698433583,0.07875396556859365
met-d-ApoA1,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Apolipoprotein A1,MR Egger,66,0.020913697712964606,0.07337631013936508,0.7765493246983995,-0.12290387016019094,0.16473126558612017,1.0211339216418662,0.8843486707708992,1.1790762177759004,1.02 [0.88:1.18],overlaps null,0.0014797321366194721,0.004128520397929018,0.7212108006504361,114.83664328931,64,9.993020565465569e-5,0.07270161006941549,0.001365271873199428,TRUE,0,142.4871698433583,0.07875396556859365
met-d-ApoA1,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Apolipoprotein A1,Weighted median,66,0.047421917834167424,0.0537283030559204,0.3774391745493505,-0.05788555615543656,0.1527293918237714,1.0485643237513322,0.9437579485446184,1.1650096751392902,1.05 [0.94:1.17],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ieu-a-1,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Adiponectin,Inverse variance weighted,11,-0.10826523129921764,0.06004926790498302,0.07139762709693302,-0.22596179639298436,0.00943133379454908,0.8973895490670213,0.797748577956688,1.0094759489730287,0.9 [0.8:1.01],overlaps null,-0.0014540876211766066,0.006582651250363213,0.8301026461531456,7.940258849786861,10,0.6346724365333591,0.07718011210014392,1.142828401502689e-4,TRUE,0,105.43260097901171,0.02826559025561699
ieu-a-1,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Adiponectin,MR Egger,11,-0.09415111335468448,0.08768370304476948,0.3108751179611679,-0.2660111713224327,0.07770894461306369,0.9101452167515952,0.7664305654102258,1.0808080378845966,0.91 [0.77:1.08],overlaps null,-0.0014540876211766066,0.006582651250363213,0.8301026461531456,7.891463384780438,9,0.5451201144032082,0.07718011210014392,1.142828401502689e-4,TRUE,0,105.43260097901171,0.02826559025561699
ieu-a-1,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Adiponectin,Weighted median,11,-0.06638600617439025,0.07509170428909,0.3766607041394511,-0.21356574658100663,0.08079373423222613,0.9357695817311005,0.8076990549534939,1.0841472510372296,0.94 [0.81:1.08],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-c-841,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Albumin,Inverse variance weighted,3,0.21183403737138526,0.1903160902291964,0.26568083370152423,-0.1611854994778397,0.5848535742206102,1.2359427477491753,0.8511341715180701,1.794728171927651,1.24 [0.85:1.79],overlaps null,0.16763439532538998,0.10063972844781924,0.34420672017039433,5.81924153090546,2,0.05449639286575744,0.012291569836283354,1.2032609864146175e-4,TRUE,5.010496710844156e-38,80.2916172020224,0.01254760753862574
met-c-841,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Albumin,MR Egger,3,-0.4072420442752758,0.3966434284436048,0.49160714091641355,-1.1846631640247411,0.37017907547418955,0.665483094432841,0.30584918315796,1.4479938916403268,0.67 [0.31:1.45],overlaps null,0.16763439532538998,0.10063972844781924,0.34420672017039433,1.5417182933039109,1,0.21436222176902991,0.012291569836283354,1.2032609864146175e-4,TRUE,5.010496710844156e-38,80.2916172020224,0.01254760753862574
met-c-841,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Albumin,Weighted median,3,0.2752801801625999,0.14824929278219148,0.06332915645970237,-0.015288433690495373,0.5658487940156952,1.3168995923254372,0.9848278411045307,1.7609418254482816,1.32 [0.98:1.76],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-d-Albumin,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Albumin,Inverse variance weighted,26,0.02867977366058284,0.07889990194583983,0.716234637993078,-0.12596403415326324,0.1833235814744289,1.029094998381028,0.8816465553780861,1.201203032249913,1.03 [0.88:1.2],overlaps null,0.00818957108194911,0.006252648381883104,0.20267115454245632,44.826919164499834,25,0.008750326935077952,0.022756214719991875,4.836595442528847e-4,TRUE,2.786181727114095e-224,99.05661207573866,0.022722006668076614
met-d-Albumin,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Albumin,MR Egger,26,-0.09871774903050153,0.12455030743612963,0.4357800932839574,-0.3428363516053156,0.14540085354431254,0.9059983908626715,0.7097543522171941,1.1565030657178197,0.91 [0.71:1.16],overlaps null,0.00818957108194911,0.006252648381883104,0.20267115454245632,41.836459284495355,24,0.01345957008861963,0.022756214719991875,4.836595442528847e-4,TRUE,2.786181727114095e-224,99.05661207573866,0.022722006668076614
met-d-Albumin,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Albumin,Weighted median,26,-0.04714321720456231,0.09014680231765113,0.6010017383819772,-0.2238309497471585,0.1295445153380339,0.9539507656446363,0.7994502702169831,1.1383097825797144,0.95 [0.8:1.14],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ukb-d-30600_irnt,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Albumin,Inverse variance weighted,186,0.008482185031855643,0.05010036071041098,0.8655576309258863,-0.08971452196054987,0.10667889202426116,1.008518260691313,0.9141921297993857,1.1125769397851086,1.01 [0.91:1.11],overlaps null,0.0013823866147101042,0.0025660311964023088,0.5907273971501072,302.39236879195283,185,1.1102270770633247e-7,0.043053563306594586,0.0032261516710208643,TRUE,0,85.0763839756563,0.043073613998040196
ukb-d-30600_irnt,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Albumin,MR Egger,186,-0.036691073218567,0.09772862565130994,0.707766936598333,-0.22823917949513445,0.15485703305800047,0.9639738867052067,0.7959338660069796,1.1674910365497555,0.96 [0.8:1.17],overlaps null,0.0013823866147101042,0.0025660311964023088,0.5907273971501072,301.91615309961225,184,9.454030892137972e-8,0.043053563306594586,0.0032261516710208643,TRUE,0,85.0763839756563,0.043073613998040196
ukb-d-30600_irnt,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Albumin,Weighted median,186,-0.019715993176153593,0.06531766549705152,0.7627680955136078,-0.1477386175503746,0.1083066311980674,0.980477095953794,0.8626565687630545,1.114389399559577,0.98 [0.86:1.11],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ieu-b-107,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),apolipoprotein A-I,Inverse variance weighted,264,0.0646506561904617,0.03759172903632014,0.08546686491681603,-0.009029132720725766,0.13833044510164916,1.0667862840962778,0.9910115074908524,1.1483549558544852,1.07 [0.99:1.15],overlaps null,-0.0013005163835472409,0.001775717656698269,0.4645857338984535,421.1195810098798,263,1.98763308230188e-9,0.08914914276657057,0.00470187245868261,TRUE,0,171.47077817020093,0.10540777721348657
ieu-b-107,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),apolipoprotein A-I,MR Egger,264,0.09910623492538202,0.06024041795879869,0.10113218656663188,-0.01896498427386341,0.21717745412462747,1.1041835961902216,0.9812137195521647,1.242564580784739,1.1 [0.98:1.24],overlaps null,-0.0013005163835472409,0.001775717656698269,0.4645857338984535,420.2591823028674,262,1.840818282350553e-9,0.08914914276657057,0.00470187245868261,TRUE,0,171.47077817020093,0.10540777721348657
ieu-b-107,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),apolipoprotein A-I,Weighted median,264,0.12730402972069327,0.054037093230192255,0.018479693837726026,0.021391326989516443,0.23321673245187008,1.1357622707812,1.0216217615921694,1.262655108011508,1.14 [1.02:1.26],positive,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-c-842,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Apolipoprotein A-I,Inverse variance weighted,11,0.06382769304322033,0.06236754919699872,0.30611312753776526,-0.058412703382897155,0.18606808946933784,1.0659087194496948,0.943260580263322,1.2045042716422176,1.07 [0.94:1.2],overlaps null,0.04536398198313328,0.01661863235157363,0.02323571484022881,26.64516076141888,10,0.002962841890612062,0.03881354605696007,3.1361610717718945e-4,TRUE,4.382210562223809e-130,77.0017658406783,0.03935594553423642
met-c-842,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Apolipoprotein A-I,MR Egger,11,-0.258584273964559,0.12772980911365617,0.07358971828186278,-0.5089346998273251,-0.008233848101792951,0.7721439566747463,0.6011356277176392,0.991799957179344,0.77 [0.6:0.99],negative,0.04536398198313328,0.01661863235157363,0.02323571484022881,14.57675166062996,9,0.10323740475975286,0.03881354605696007,3.1361610717718945e-4,TRUE,4.382210562223809e-130,77.0017658406783,0.03935594553423642
met-c-842,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Apolipoprotein A-I,Weighted median,11,0.03746732945750029,0.04946100158955746,0.4487428497677359,-0.05947623365803233,0.1344108925730329,1.0381780786867199,0.9422579273492433,1.1438627277965716,1.04 [0.94:1.14],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ukb-d-30630_irnt,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Apoliprotein A,Inverse variance weighted,222,0.0705508873536756,0.03405319734560946,0.03828554030946372,0.0038066205562810596,0.13729515415107013,1.0730991752185874,1.0038138749382832,1.147166689567438,1.07 [1:1.15],positive,4.0534164415723844e-4,0.001805687671552234,0.822591797288421,351.31623962785636,221,5.472417859393488e-8,0.07527540442709078,0.003973668670929626,TRUE,0,171.6448063278531,0.09703784729333688
ukb-d-30630_irnt,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Apoliprotein A,MR Egger,222,0.06187220669105546,0.051568511790362655,0.2315052014303763,-0.03920207641805534,0.16294648980016627,1.063826386146892,0.9615563816431644,1.176973707905089,1.06 [0.96:1.18],overlaps null,4.0534164415723844e-4,0.001805687671552234,0.822591797288421,351.2357882912548,220,4.3625528161626014e-8,0.07527540442709078,0.003973668670929626,TRUE,0,171.6448063278531,0.09703784729333688
ukb-d-30630_irnt,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Apoliprotein A,Weighted median,222,0.04173310438426648,0.05168945058095452,0.4194467416629211,-0.05957821875440438,0.14304442752293733,1.0426161719277995,0.9421618359837421,1.153781060161873,1.04 [0.94:1.15],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-132,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Apolipoprotein E (isoform E2),Wald ratio,1,-0.11205501618122977,0.06755663430420712,0.09717976041885233,-0.24446601941747576,0.020355987055016192,0.8939950719524721,0.7831225988753395,1.020564583148404,0.89 [0.78:1.02],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-132,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Apolipoprotein E (isoform E2),NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-131,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Apolipoprotein E (isoform E3),Wald ratio,1,-0.024941111265068587,0.02979077178883192,0.40247492954739417,-0.08333102397117914,0.033448801441041974,0.9753673484863816,0.9200465393475279,1.0340145023185678,0.98 [0.92:1.03],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-131,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Apolipoprotein E (isoform E3),NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-127,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Apolipoprotein B,Wald ratio,1,-0.04220398593200469,0.050410316529894486,0.40247492954739417,-0.14100820633059788,0.056600234466588496,0.9586742045746776,0.868482184616499,1.058232680872693,0.96 [0.87:1.06],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-127,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Apolipoprotein B,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-c-843,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Apolipoprotein B,Inverse variance weighted,20,-0.03183151182548465,0.03650621185346858,0.383236844604264,-0.10338368705828307,0.03972066340731376,0.968669777733101,0.901780905432025,1.0405200782599902,0.97 [0.9:1.04],overlaps null,0.005419433909880857,0.008893255951316287,0.5498833145404719,30.055414036062356,19,0.051097441771100774,0.06876637281847174,3.8623740829346744e-4,TRUE,1.1225928361214944e-241,74.89558402093132,0.07071718421634327
met-c-843,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Apolipoprotein B,MR Egger,20,-0.0644065914563062,0.06508300143451759,0.3354834582941202,-0.19196927426796068,0.06315609135534828,0.9376236922353451,0.8253322270389518,1.0651930936892275,0.94 [0.83:1.07],overlaps null,0.005419433909880857,0.008893255951316287,0.5498833145404719,29.447883862998456,18,0.043172649343081716,0.06876637281847174,3.8623740829346744e-4,TRUE,1.1225928361214944e-241,74.89558402093132,0.07071718421634327
met-c-843,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Apolipoprotein B,Weighted median,20,-0.06161819543656547,0.04140325352285312,0.13668622754787127,-0.1427685723413576,0.01953218146822664,0.9402418068806637,0.8669546829732,1.0197241825540078,0.94 [0.87:1.02],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ieu-b-108,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),apolipoprotein B,Inverse variance weighted,178,-0.0334012347690922,0.034528029684719304,0.3333612046978825,-0.10107617295114205,0.034273703412957636,0.9671504273497693,0.9038641802615015,1.0348678148217156,0.97 [0.9:1.03],overlaps null,0.0014440521348624785,0.001832189844919314,0.4316654874227912,247.77405932604225,177,3.5388446452844566e-4,0.06145698502892919,0.002699950065243884,TRUE,0,240.59553912341835,0.08978558558416183
ieu-b-108,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),apolipoprotein B,MR Egger,178,-0.059039981017221306,0.04746518974748017,0.2152057659579411,-0.15207175292228245,0.03399179088783983,0.9426690795349671,0.8589266480329638,1.034576113741902,0.94 [0.86:1.03],overlaps null,0.0014440521348624785,0.001832189844919314,0.4316654874227912,246.9026186436186,176,3.372733383953382e-4,0.06145698502892919,0.002699950065243884,TRUE,0,240.59553912341835,0.08978558558416183
ieu-b-108,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),apolipoprotein B,Weighted median,178,-0.0074737780422179335,0.05257706967649661,0.8869623122316481,-0.1105248346081513,0.09557727852371542,0.9925540811891191,0.8953640938969477,1.1002938478327726,0.99 [0.9:1.1],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-d-ApoB,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Apolipoprotein B,Inverse variance weighted,52,-0.018884723836405604,0.034684833921682014,0.586120619918024,-0.08686699832290234,0.04909755065009114,0.9812924753549809,0.916799023332343,1.0503228054151605,0.98 [0.92:1.05],overlaps null,0.0010636936454069502,0.003524280919948111,0.7640421590386308,70.57692719331331,51,0.03604185362300127,0.060914987589111055,7.79310546732439e-4,TRUE,0,188.4836080671642,0.08129412305145553
met-d-ApoB,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Apolipoprotein B,MR Egger,52,-0.030105850366960892,0.05105975436942245,0.5581005616169247,-0.13018296893102888,0.0699712681971071,0.9703428169690562,0.8779347814356049,1.0724773666032341,0.97 [0.88:1.07],overlaps null,0.0010636936454069502,0.003524280919948111,0.7640421590386308,70.44857765317485,50,0.0298614056932394,0.060914987589111055,7.79310546732439e-4,TRUE,0,188.4836080671642,0.08129412305145553
met-d-ApoB,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Apolipoprotein B,Weighted median,52,-0.03862425232440222,0.04497349696431048,0.39043843701852093,-0.12677230637445075,0.04952380172564632,0.962112152641357,0.8809342328724955,1.0507706020707719,0.96 [0.88:1.05],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-275,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Basigin,Wald ratio,1,0.05007743933918431,0.0743417656169334,0.5005585872645254,-0.09563242127000514,0.19578729994837374,1.0513525092672704,0.9087980094986585,1.2162681775154325,1.05 [0.91:1.22],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-275,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Basigin,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ieu-b-35,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),C-Reactive protein level,Inverse variance weighted,53,0.03214111416777163,0.05595322469681895,0.5656780259452154,-0.07752720623799352,0.14180943457353679,1.0326632184344409,0.9254018473512534,1.152357028203131,1.03 [0.93:1.15],overlaps null,-0.0010157253183544952,0.00448157369573433,0.8216059549067841,146.08431284764114,52,7.151972468799338e-11,0.03172797569493132,0.0014758395484059576,TRUE,0,166.0407128758088,0.04128657678290181
ieu-b-35,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),C-Reactive protein level,MR Egger,53,0.04634125985758063,0.08434708782620015,0.5851209267494762,-0.11897903228177166,0.21166155199693293,1.0474317963984807,0.887826416260919,1.2357295840858638,1.05 [0.89:1.24],overlaps null,-0.0010157253183544952,0.00448157369573433,0.8216059549067841,145.93732288816204,51,4.373917593964929e-11,0.03172797569493132,0.0014758395484059576,TRUE,0,166.0407128758088,0.04128657678290181
ieu-b-35,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),C-Reactive protein level,Weighted median,53,0.0671093891514031,0.04832009219838072,0.16487818419653397,-0.027597991557423096,0.1618167698602293,1.0694124538973777,0.9727793537189199,1.175644808022171,1.07 [0.97:1.18],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-670,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),C-reactive protein,Inverse variance weighted,3,0.04686887437690345,0.04391856637029589,0.28589201440696776,-0.039211515708876495,0.1329492644626834,1.0479845824384078,0.9615473052756744,1.142192047133584,1.05 [0.96:1.14],overlaps null,-0.13193663291068716,0.11517665003415992,0.45688851198836405,2.4984073412308523,2,0.2867330399150154,0.04378392349385333,4.612646602568968e-5,TRUE,2.117183040164611e-31,49.93279320192895,0.043460151453047685
prot-a-670,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),C-reactive protein,MR Egger,3,0.742621155211526,0.6087423978728227,0.437135600543484,-0.45051394461920635,1.9357562550422585,2.1014364931010574,0.637300530261022,6.929282379112685,2.1 [0.64:6.93],overlaps null,-0.13193663291068716,0.11517665003415992,0.45688851198836405,1.0805298948137634,1,0.29857904516306955,0.04378392349385333,4.612646602568968e-5,TRUE,2.117183040164611e-31,49.93279320192895,0.043460151453047685
prot-a-670,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),C-reactive protein,Weighted median,3,0.04799765871030683,0.046921510296184694,0.3063385436342679,-0.04396850147021517,0.13996381889082884,1.0491681989149044,0.9569841005905083,1.150232181428221,1.05 [0.96:1.15],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ukb-d-30710_irnt,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),C-reactive protein,Inverse variance weighted,180,0.025419563881007586,0.04009021877737835,0.5260423209927534,-0.053157264922653984,0.10399639268466915,1.0257453959733585,0.9482308773001624,1.1095964522440698,1.03 [0.95:1.11],overlaps null,-1.1111529835830679e-4,0.002064560181192966,0.9571386733215869,346.5670924478412,179,8.647920539832409e-13,0.050299345618834895,0.003949028999412522,TRUE,0,174.79561264571916,0.08221071287530522
ukb-d-30710_irnt,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),C-reactive protein,MR Egger,180,0.027625173356660895,0.057407919165649295,0.6309593941353763,-0.08489434820801171,0.1401446949213335,1.028010286552216,0.9186093319968035,1.1504402496760686,1.03 [0.92:1.15],overlaps null,-1.1111529835830679e-4,0.002064560181192966,0.9571386733215869,346.56145278848396,178,6.162528291302892e-13,0.050299345618834895,0.003949028999412522,TRUE,0,174.79561264571916,0.08221071287530522
ukb-d-30710_irnt,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),C-reactive protein,Weighted median,180,0.0516490393301161,0.045143261106399275,0.2525763413057563,-0.03683175243842648,0.14012983109865867,1.0530061139234757,0.9638382851492443,1.150423149863284,1.05 [0.96:1.15],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-b-51,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),cathepsin D,Inverse variance weighted,2,0.03139478416338552,0.041915413046348236,0.4538551952828116,-0.05075942540745702,0.11354899373422807,1.0318927984196447,0.950507310937826,1.1202467726205376,1.03 [0.95:1.12],overlaps null,NA,NA,NA,1.857993981021096,1,0.17285650224357355,0.04491915770494122,2.864664582894942e-5,TRUE,1.7034780655197153e-33,79.95059209061124,0.04503115572282335
prot-a-495,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cyclin-dependent kinase inhibitor 1B,Wald ratio,1,-0.02729430379746835,0.03085443037974683,0.3763641062167796,-0.08776898734177213,0.03318037974683544,0.9730748197642208,0.9159724535152762,1.0337369876411675,0.97 [0.92:1.03],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-495,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cyclin-dependent kinase inhibitor 1B,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-2218,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),"Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A",Wald ratio,1,-0.008317338451695458,0.08509277031349968,0.9221352892802033,-0.17509916826615485,0.15846449136276392,0.991717154910529,0.8393737773995646,1.1717103176498929,0.99 [0.84:1.17],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-2218,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),"Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A",NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-346,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Calcium/calmodulin-dependent protein kinase type 1,Inverse variance weighted,3,-0.020211062036503788,0.011736161261018356,0.0850480296400668,-0.043213938108099766,0.0027918140350921897,0.9799918124095979,0.9577064782365188,1.0027957147770996,0.98 [0.96:1],overlaps null,0.02778602331256941,0.07119412935904723,0.7631114278225644,0.1856586601635494,2,0.9113490268878013,0.2905704839534254,3.097056412884653e-5,TRUE,2.3114097208767666e-251,962.121209780234,0.46679506533379456
prot-a-346,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Calcium/calmodulin-dependent protein kinase type 1,MR Egger,3,-0.04814880564108636,0.07253857561484318,0.6269450509080141,-0.190324413846179,0.09402680256400628,0.9529919659454316,0.8266909004617671,1.0985891905296723,0.95 [0.83:1.1],overlaps null,0.02778602331256941,0.07119412935904723,0.7631114278225644,0.03333603185809398,1,0.8551263416291964,0.2905704839534254,3.097056412884653e-5,TRUE,2.3114097208767666e-251,962.121209780234,0.46679506533379456
prot-a-346,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Calcium/calmodulin-dependent protein kinase type 1,Weighted median,3,-0.02046823427318745,0.011569590824741608,0.07687039350430099,-0.043144632289681004,0.0022081637433061,0.9797398181276242,0.9577728551679251,1.0022106035323521,0.98 [0.96:1],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-347,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Calcium/calmodulin-dependent protein kinase type 1D,Inverse variance weighted,3,0.0232484506780483,0.02996225819169466,0.4377935564467068,-0.03547757537767324,0.08197447673376983,1.023520802397373,0.965144376985479,1.0854281058054838,1.02 [0.97:1.09],overlaps null,0.0025682709253295015,0.026271247659190693,0.9379613351460913,0.10604914585680963,2,0.9483567082944782,0.0728296371905048,6.997860329782324e-6,TRUE,1.8595861817432017e-54,84.64450553078537,0.07151176314786167
prot-a-347,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Calcium/calmodulin-dependent protein kinase type 1D,MR Egger,3,0.014042118759663087,0.09882456357485948,0.9101433294067806,-0.1796540258470615,0.20773826336638765,1.014141172407272,0.8355592433110401,1.2308909581277165,1.01 [0.84:1.23],overlaps null,0.0025682709253295015,0.026271247659190693,0.9379613351460913,0.09649217474047099,1,0.7560804765124359,0.0728296371905048,6.997860329782324e-6,TRUE,1.8595861817432017e-54,84.64450553078537,0.07151176314786167
prot-a-347,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Calcium/calmodulin-dependent protein kinase type 1D,Weighted median,3,0.025135997650508876,0.03171026894198215,0.4279660928174877,-0.03701612947577614,0.0872881247767939,1.0254545704540678,0.9636605918835266,1.0912110393658536,1.03 [0.96:1.09],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-348,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Calcium/calmodulin-dependent protein kinase type II subunit alpha,Wald ratio,1,-0.027707226968367586,0.03578850150080813,0.43881634294658034,-0.09785268990995152,0.04243823597321636,0.9726730975700307,0.906782472123318,1.043351612786594,0.97 [0.91:1.04],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-348,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Calcium/calmodulin-dependent protein kinase type II subunit alpha,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-349,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Calcium/calmodulin-dependent protein kinase type II subunit beta,Wald ratio,1,-0.02295373665480427,0.027758007117437717,0.40828066255910844,-0.0773594306049822,0.03145195729537366,0.9773076962507429,0.9255571202571234,1.031951796649347,0.98 [0.93:1.03],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-349,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Calcium/calmodulin-dependent protein kinase type II subunit beta,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-c-875,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cholesterol esters in large HDL,Inverse variance weighted,13,0.03885047528667834,0.030999707382555287,0.21011365880941327,-0.02190895118313002,0.09960990175648671,1.0396150238894974,0.9783293067220996,1.1047398769213892,1.04 [0.98:1.1],overlaps null,0.005555197004976696,0.011752116062104655,0.6456690659516949,11.504727377263464,12,0.4862286107185478,0.0648910965646224,1.33236451658846e-4,TRUE,1.4460270174208626e-227,104.94930175813884,0.06615518445625727
met-c-875,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cholesterol esters in large HDL,MR Egger,13,0.003718424913918729,0.08067772280577094,0.9640647328094496,-0.15440991178539232,0.16184676161322975,1.003725346832725,0.8569206871196287,1.1756800681996242,1 [0.86:1.18],overlaps null,0.005555197004976696,0.011752116062104655,0.6456690659516949,11.275684383144759,11,0.42046477890988027,0.0648910965646224,1.33236451658846e-4,TRUE,1.4460270174208626e-227,104.94930175813884,0.06615518445625727
met-c-875,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cholesterol esters in large HDL,Weighted median,13,0.04450737011280459,0.040880125981052846,0.27627350180045024,-0.03561767681005899,0.12463241703566817,1.0455126822284668,0.9650091683474873,1.132732003543984,1.05 [0.97:1.13],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-c-881,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cholesterol esters in large VLDL,Inverse variance weighted,25,-0.03038475161734897,0.033133385390298295,0.35911991059191367,-0.09532618698233362,0.034556683747635694,0.9700722248800885,0.9090763572273686,1.0351607035012154,0.97 [0.91:1.04],overlaps null,0.0023851836065454956,0.007519658563898397,0.7539585483213939,46.59548536132686,24,0.0037517224116896744,0.10270486471872796,5.753307884933302e-4,TRUE,0,90.95343554997712,0.105657415004876
met-c-881,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cholesterol esters in large VLDL,MR Egger,25,-0.04315431394218061,0.05254779510485116,0.4199413924574832,-0.14614799234768888,0.05983936446332766,0.9577635823888557,0.8640298239201847,1.0616659915608095,0.96 [0.86:1.06],overlaps null,0.0023851836065454956,0.007519658563898397,0.7539585483213939,46.39254531599957,23,0.0026722271074160254,0.10270486471872796,5.753307884933302e-4,TRUE,0,90.95343554997712,0.105657415004876
met-c-881,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cholesterol esters in large VLDL,Weighted median,25,-0.039290568388423285,0.035642578168170444,0.27030987705091564,-0.10915002159803736,0.03056888482119078,0.9614712953891136,0.8965958986586116,1.0310409106714034,0.96 [0.9:1.03],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-c-887,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cholesterol esters in large VLDL,Inverse variance weighted,12,-0.11437321456557302,0.04619803131284238,0.01329692273970576,-0.20492135593874408,-0.023825073192401958,0.8919250143502039,0.8147113861041858,0.9764565032381645,0.89 [0.81:0.98],negative,0.010662113712083972,0.013421413863074686,0.4453998888647245,16.077822240377426,11,0.138266260317091,0.04154318433727714,2.805212656054918e-4,TRUE,1.5800329691139284e-131,69.97993272180987,0.04244046154729363
met-c-887,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cholesterol esters in large VLDL,MR Egger,12,-0.1992159837472161,0.11668111593655102,0.11856030494980621,-0.42791097098285613,0.02947900348842389,0.8193729029901398,0.651869447511614,1.0299178105636368,0.82 [0.65:1.03],overlaps null,0.010662113712083972,0.013421413863074686,0.4453998888647245,15.123402126912154,10,0.12762718969399453,0.04154318433727714,2.805212656054918e-4,TRUE,1.5800329691139284e-131,69.97993272180987,0.04244046154729363
met-c-887,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cholesterol esters in large VLDL,Weighted median,12,-0.07964444120692199,0.0534444913359947,0.13616447468503207,-0.1843956442254716,0.025106761811627618,0.9234446268786769,0.8316067183346046,1.0254245908677073,0.92 [0.83:1.03],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-c-899,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cholesterol esters in medium HDL,Inverse variance weighted,7,0.050167776163269395,0.06389408404291323,0.43235336832394256,-0.07506462856084054,0.17540018088737933,1.051447489403989,0.9276835295396837,1.191723025979044,1.05 [0.93:1.19],overlaps null,-0.004500794278243882,0.020819755748446713,0.837391015613315,8.082676814235445,6,0.23210857089251327,0.02069469750326165,9.093743636152184e-5,TRUE,1.2404423784941259e-68,59.17815405770613,0.02104994549606213
met-c-899,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cholesterol esters in medium HDL,MR Egger,7,0.08891420150732951,0.1922968232140032,0.6632324323199427,-0.2879875719921168,0.46581597500677574,1.0929868756768268,0.7497709103399228,1.5933137628134808,1.09 [0.75:1.59],overlaps null,-0.004500794278243882,0.020819755748446713,0.837391015613315,8.007830241483184,5,0.1558046152661057,0.02069469750326165,9.093743636152184e-5,TRUE,1.2404423784941259e-68,59.17815405770613,0.02104994549606213
met-c-899,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cholesterol esters in medium HDL,Weighted median,7,0.0604180490881361,0.06874039256430584,0.37943879075840303,-0.07431312033790334,0.19514921851417555,1.062280539144277,0.9283809533674635,1.2154923469202266,1.06 [0.93:1.22],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-c-905,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cholesterol esters in medium LDL,Inverse variance weighted,24,-0.043359543224810025,0.03208733631574981,0.17660009387848727,-0.10625072240367964,0.019531635954059594,0.9575670414245839,0.8991991704335591,1.0197236262801714,0.96 [0.9:1.02],overlaps null,-0.0015480049344020542,0.007797018671735761,0.8444473834482873,39.33144108847408,23,0.018241329773270056,0.0973209153939637,5.184790780519991e-4,TRUE,0,89.28137176236022,0.10017192616269002
met-c-905,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cholesterol esters in medium LDL,MR Egger,24,-0.03528173581036109,0.052248048521956476,0.5065379043806191,-0.13768791091339577,0.0671244392926736,0.9653334089520267,0.8713705945675921,1.0694285488270006,0.97 [0.87:1.07],overlaps null,-0.0015480049344020542,0.007797018671735761,0.8444473834482873,39.26109705241073,22,0.013170424991981615,0.0973209153939637,5.184790780519991e-4,TRUE,0,89.28137176236022,0.10017192616269002
met-c-905,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cholesterol esters in medium LDL,Weighted median,24,-0.04711749682991651,0.03346736221367577,0.15917132365741077,-0.11271352676872101,0.018478533108887994,0.9539753019312622,0.8934065605241962,1.0186503176794115,0.95 [0.89:1.02],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-c-910,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cholesterol esters in medium VLDL,Inverse variance weighted,14,-0.06654568789152437,0.03441862955358402,0.053184403835345305,-0.13400620181654904,9.148260335002933e-4,0.9356201683670565,0.8745846405730172,1.0009152446144693,0.94 [0.87:1],overlaps null,0.00535165214702124,0.011164798854680691,0.6403189610301664,12.510041869079028,13,0.48632819838750996,0.053537526627753025,1.732910718743807e-4,TRUE,3.3275201445283494e-182,79.86292168778593,0.05487222537626808
met-c-910,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cholesterol esters in medium VLDL,MR Egger,14,-0.10865159345415978,0.09448885940139698,0.27259124868701756,-0.29384975788089784,0.0765465709725783,0.8970428986776291,0.7453884717745506,1.0795524649747301,0.9 [0.75:1.08],overlaps null,0.00535165214702124,0.011164798854680691,0.6403189610301664,12.275016477424575,12,0.42385320094475254,0.053537526627753025,1.732910718743807e-4,TRUE,3.3275201445283494e-182,79.86292168778593,0.05487222537626808
met-c-910,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cholesterol esters in medium VLDL,Weighted median,14,-0.08130487328011426,0.0484405484775795,0.09325994935195693,-0.1762483482961701,0.013638601735941544,0.9219125820825407,0.8384097398493027,1.013732031732914,0.92 [0.84:1.01],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-c-943,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cholesterol esters in very large HDL,Inverse variance weighted,13,0.05285935090018009,0.04812373676882095,0.27202769986342906,-0.04146317316670898,0.14718187496706917,1.0542813509679103,0.9593846657900631,1.1585646577782052,1.05 [0.96:1.16],overlaps null,0.024377027115735892,0.015056226861442491,0.13372259455594782,22.83586047879645,12,0.029152198798457103,0.04891839391555753,2.5913237158419356e-4,TRUE,1.0307142050585652e-160,76.47810438266569,0.04908926012245622
met-c-943,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cholesterol esters in very large HDL,MR Egger,13,-0.12743264017936226,0.1201677431487446,0.3116665433223444,-0.36296141675090166,0.10809613639217713,0.8803527142379628,0.6956132720014832,1.1141548510657164,0.88 [0.7:1.11],overlaps null,0.024377027115735892,0.015056226861442491,0.13372259455594782,18.441197175657432,11,0.07189186116849774,0.04891839391555753,2.5913237158419356e-4,TRUE,1.0307142050585652e-160,76.47810438266569,0.04908926012245622
met-c-943,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Cholesterol esters in very large HDL,Weighted median,13,-2.581635395113558e-4,0.0493791773464267,0.9958285298578031,-0.09704135113850769,0.09652502405948497,0.9997418697818277,0.9075184784350714,1.101337140725089,1 [0.91:1.1],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-d-Total_CE,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Total esterified cholesterol,Inverse variance weighted,61,0.014049012855140926,0.04153015496903328,0.7351487097553489,-0.06735009088416428,0.09544811659444614,1.014148164017443,0.934867855325645,1.1001517409342214,1.01 [0.93:1.1],overlaps null,-2.3292066156863986e-4,0.003971860370261953,0.9534348630293019,103.86613231076471,60,3.8201028325362895e-4,0.05865853344309517,0.0011083821585417316,TRUE,0,154.31493160788077,0.07565113340698283
met-d-Total_CE,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Total esterified cholesterol,MR Egger,61,0.016853387182363525,0.0635670300702326,0.7918351368381259,-0.10773799175529236,0.1414447661200194,1.0169962067149858,0.8978628130743812,1.1519368765604372,1.02 [0.9:1.15],overlaps null,-2.3292066156863986e-4,0.003971860370261953,0.9534348630293019,103.86007855744947,59,2.8166165868666624e-4,0.05865853344309517,0.0011083821585417316,TRUE,0,154.31493160788077,0.07565113340698283
met-d-Total_CE,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Total esterified cholesterol,Weighted median,61,-0.033519346695581785,0.048694715992607863,0.4912280200323028,-0.12896099004109318,0.06192229664992962,0.967036202095405,0.8790082549526691,1.0638796745014178,0.97 [0.88:1.06],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-879,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Dynactin-associated protein,Inverse variance weighted,2,0.00780264004850944,0.05428927038731549,0.8857188703282405,-0.09860432991062892,0.11420961000764782,1.00783315997139,0.9061011542303243,1.1209870703682234,1.01 [0.91:1.12],overlaps null,NA,NA,NA,0.0069086705936233644,1,0.9337573849828714,0.03155056072184482,5.851721826187809e-7,TRUE,3.8328030340449526e-24,53.17767634385489,0.031240966840827333
prot-a-908,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Epidermal growth factor,Wald ratio,1,-0.03730218538055765,0.04559155990957046,0.4132533754936404,-0.12666164280331574,0.052057272042200446,0.963384970504454,0.8810317255949872,1.0534360732209578,0.96 [0.88:1.05],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-908,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Epidermal growth factor,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-928,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),ELAV-like protein 1,Wald ratio,1,-0.02701092353525323,0.03118172790466733,0.38635744446607045,-0.0881271102284012,0.034105263157894736,0.9733506090365731,0.9156444815467899,1.0346935161029032,0.97 [0.92:1.03],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-928,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),ELAV-like protein 1,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-905,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Ephrin-B2,Wald ratio,1,-0.088557516737675,0.10194765672550214,0.38503492261867706,-0.2883749239196592,0.11125989044430921,0.9152504670010467,0.7494805413737073,1.117685344852665,0.92 [0.75:1.12],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-905,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Ephrin-B2,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-962,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Ephrin type-B receptor 2,Wald ratio,1,-0.005413385826771654,0.05142716535433071,0.9161669962598081,-0.10621062992125985,0.09538385826771653,0.9946012401423768,0.8992352222831909,1.100081049295488,0.99 [0.9:1.1],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-962,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Ephrin type-B receptor 2,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-1320,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Histone deacetylase 8,Wald ratio,1,-0.09453630481667864,0.07584471603163193,0.21260088667789048,-0.24319194823867724,0.054119338605319936,0.9097947040965025,0.7841209886828182,1.0556105697316858,0.91 [0.78:1.06],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-1320,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Histone deacetylase 8,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-1397,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Intercellular adhesion molecule 1,Inverse variance weighted,3,0.007516763603067384,0.015501273985575404,0.6277383198458151,-0.022865733408660407,0.03789926061479518,1.0075450853888492,0.9773937062850199,1.0386265970032698,1.01 [0.98:1.04],overlaps null,-0.0361414166847193,0.016749136108461918,0.27627307900906756,4.99975666594231,2,0.08209498626936537,0.2805055300831925,5.690193546637492e-5,TRUE,7.181195679829288e-239,3130.476198109417,0.7401569488696367
prot-a-1397,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Intercellular adhesion molecule 1,MR Egger,3,0.04271723290326522,0.019032517456984234,0.2668355497554373,0.005413498687576124,0.08002096711895432,1.0436427452941726,1.0054281781487233,1.0833097813218873,1.04 [1.01:1.08],positive,-0.0361414166847193,0.016749136108461918,0.27627307900906756,0.34362212642345036,1,0.5577458864181676,0.2805055300831925,5.690193546637492e-5,TRUE,7.181195679829288e-239,3130.476198109417,0.7401569488696367
prot-a-1397,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Intercellular adhesion molecule 1,Weighted median,3,0.01094696450762962,0.009849352717757767,0.2663790062120663,-0.008357766819175603,0.030251695834434843,1.0110071017634006,0.9916770622154005,1.030713927710082,1.01 [0.99:1.03],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-1426,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Interferon alpha/beta receptor 1,Wald ratio,1,0.1297894373489817,0.06040731791508457,0.03166838857618473,0.011391094235415955,0.24818778046254747,1.1385886138453085,1.0114562197982495,1.28170058792734,1.14 [1.01:1.28],positive,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-1426,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Interferon alpha/beta receptor 1,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-1443,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Insulin-like growth factor I,Inverse variance weighted,3,-0.0037322689525865946,0.04159957821384574,0.9285105858857485,-0.08526744225172424,0.07780290434655106,0.99627468730628,0.9182666682534125,1.0809095950908565,1 [0.92:1.08],overlaps null,-0.0013631898959008517,0.018676824234765247,0.9536164462852226,0.3087985531409711,2,0.8569298007037566,0.03721010842626091,3.150559734683014e-6,TRUE,5.020030349977112e-28,42.21179732044945,0.03698857426777589
prot-a-1443,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Insulin-like growth factor I,MR Egger,3,0.002611003376269988,0.09635110232941392,0.982752561904346,-0.1862371571893813,0.19145916394192128,1.0026144150142053,0.8300767129766435,1.2110153790358917,1 [0.83:1.21],overlaps null,-0.0013631898959008517,0.018676824234765247,0.9536164462852226,0.30347125928443935,1,0.5817143923305392,0.03721010842626091,3.150559734683014e-6,TRUE,5.020030349977112e-28,42.21179732044945,0.03698857426777589
prot-a-1443,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Insulin-like growth factor I,Weighted median,3,-5.564349571339292e-4,0.048155414476643565,0.9907806632596555,-0.0949410473313553,0.09382817741708746,0.999443719824087,0.9094265460097678,1.0983710047596074,1 [0.91:1.1],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ukb-d-30770_irnt,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),IGF-1,Inverse variance weighted,318,0.017326317871688403,0.03896186189345629,0.6565369795176786,-0.059038931439485916,0.09369156718286273,1.017477289182433,0.9426700689399641,1.0982209662880102,1.02 [0.94:1.1],overlaps null,-0.0029468091582332,0.0021141959238055504,0.16435127587696197,576.5669047503387,317,2.4707953256061653e-17,0.08356626327904101,0.006101997226761512,TRUE,0,105.22406103870784,0.08753534522247032
ukb-d-30770_irnt,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),IGF-1,MR Egger,318,0.11096959345828011,0.07763567304901663,0.15388762783420892,-0.04119632571779247,0.2631355126343527,1.1173609312561483,0.9596407093014183,1.3010030093517644,1.12 [0.96:1.3],overlaps null,-0.0029468091582332,0.0021141959238055504,0.16435127587696197,573.0438907930651,316,4.078541567389009e-17,0.08356626327904101,0.006101997226761512,TRUE,0,105.22406103870784,0.08753534522247032
ukb-d-30770_irnt,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),IGF-1,Weighted median,318,0.04086909570898857,0.05497468994186432,0.45722951233499515,-0.0668812965770655,0.14861948799504265,1.041715731560429,0.9353062187972331,1.1602314232187698,1.04 [0.94:1.16],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-1444,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Insulin-like growth factor 1 receptor,Wald ratio,1,-0.15557595227168425,0.06516750803120698,0.016971529374236172,-0.2833042680128499,-0.027847636530518582,0.8559220652348283,0.7532905507677479,0.9725365345538859,0.86 [0.75:0.97],negative,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-1444,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Insulin-like growth factor 1 receptor,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ebi-a-GCST90010149,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Lipoprotein lipase levels,Inverse variance weighted,3,0.025869882848840883,0.028837481179476734,0.3696696573158342,-0.030651580262933513,0.08239134596061529,1.0262074126009508,0.9698134163525045,1.0858806817066762,1.03 [0.97:1.09],overlaps null,-0.019967400214829106,0.04511738075335356,0.7347496372817321,2.6725533558727417,2,0.2628224215900287,0.11081870455960946,4.241159480314336e-5,TRUE,4.380799032668235e-34,56.923663453025846,0.11634716279363165
ebi-a-GCST90010149,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Lipoprotein lipase levels,MR Egger,3,0.08546141365034074,0.13971922349708327,0.6505257492147494,-0.18838826440394243,0.35931109170462394,1.089219531527483,0.8282930480857184,1.4323423220837799,1.09 [0.83:1.43],overlaps null,-0.019967400214829106,0.04511738075335356,0.7347496372817321,2.234829949682747,1,0.13493146830091804,0.11081870455960946,4.241159480314336e-5,TRUE,4.380799032668235e-34,56.923663453025846,0.11634716279363165
ebi-a-GCST90010149,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Lipoprotein lipase levels,Weighted median,3,0.015490193039325511,0.027030456984720296,0.5666010797332462,-0.03748950265072627,0.06846988872937729,1.0156107879544136,0.9632045287621126,1.0708683792579332,1.02 [0.96:1.07],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ukb-d-30790_irnt,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Lipoprotein A,Inverse variance weighted,20,-0.008368906372741286,0.013837483875184941,0.5453120797375015,-0.03549037476810377,0.018752562022621197,0.9916660154371744,0.9651320238048329,1.0189294955690993,0.99 [0.97:1.02],overlaps null,-0.0098486610740665375,0.007585309412360117,0.21054436336216692,16.507740442449414,19,0.6231786719370334,0.034547544453679586,1.9073339261731738e-4,TRUE,0,7039.240290698945,0.28047139457405407
ukb-d-30790_irnt,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Lipoprotein A,MR Egger,20,0.00441049214486392,0.016980908586308824,0.7980177188057912,-0.02887208868430137,0.03769307297402921,1.004420232680264,0.9715407275718253,1.0384124671118242,1 [0.97:1.04],overlaps null,-0.0098486610740665375,0.007585309412360117,0.21054436336216692,14.82193371456325,18,0.6741554002293055,0.034547544453679586,1.9073339261731738e-4,TRUE,0,7039.240290698945,0.28047139457405407
ukb-d-30790_irnt,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Lipoprotein A,Weighted median,20,0.0073872594738744225,0.015691854069778403,0.6378047474081151,-0.023368774502891248,0.03814329345064009,1.0074146125885088,0.9769021607296885,1.0388800869257948,1.01 [0.98:1.04],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ieu-b-110,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),LDL cholesterol,Inverse variance weighted,160,-0.0025406999190050465,0.044636585193822,0.9546091813962728,-0.09002840689889616,0.084947007060886065,0.9974625249273338,0.9139052236891959,1.0886593739098396,1 [0.91:1.09],overlaps null,0.003298371564556892,0.0022814429914733074,0.1502309891541204,274.9881578407041,159,3.1526964825990435e-8,0.05191116066520105,0.002945491874401015,TRUE,0,188.01560847654528,0.065436208863487
ieu-b-110,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),LDL cholesterol,MR Egger,160,-0.07415496071529519,0.06657735127099841,0.2670493905301253,-0.20464656920645208,0.056336647775861684,0.9285277973607738,0.814935288745063,1.0579537815810083,0.93 [0.81:1.06],overlaps null,0.003298371564556892,0.0022814429914733074,0.1502309891541204,271.3978700579925,158,5.1964156842433695e-8,0.05191116066520105,0.002945491874401015,TRUE,0,188.01560847654528,0.065436208863487
ieu-b-110,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),LDL cholesterol,Weighted median,160,-0.020153566776317813,0.058748885494737016,0.7315638979820127,-0.13530138234600236,0.09499424879336674,0.9800481589136455,0.8734526288132284,1.0996525307789873,0.98 [0.87:1.1],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-d-LDL_C,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),LDL cholesterol,Inverse variance weighted,48,-0.013675350849280479,0.03780770488194076,0.7175702178822927,-0.08777845241788437,0.06042775071932341,0.986417731964654,0.9159637838073168,1.062290845048277,0.99 [0.92:1.06],overlaps null,0.0011666943338983272,0.003760276349879717,0.757758400421271,78.57579212732563,47,0.002636195704496066,0.05360897676452543,8.356418933628857e-4,TRUE,0,214.88736959639002,0.082290553771505
met-d-LDL_C,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),LDL cholesterol,MR Egger,48,-0.02450465515395762,0.051726868806799435,0.6379320484787732,-0.1258893180152845,0.07688000770736926,0.9757931464405069,0.8817124310647241,1.0799124874427093,0.98 [0.88:1.08],overlaps null,0.0011666943338983272,0.003760276349879717,0.757758400421271,78.41169625076034,46,0.002032656311947756,0.05360897676452543,8.356418933628857e-4,TRUE,0,214.88736959639002,0.082290553771505
met-d-LDL_C,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),LDL cholesterol,Weighted median,48,-0.033028468787315225,0.040173330756447495,0.41099202867313855,-0.11176819706995231,0.045711259495321864,0.9675110153316374,0.8942515236003548,1.046772121806743,0.97 [0.89:1.05],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ukb-d-30780_irnt,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),LDL direct,Inverse variance weighted,149,-0.006574331846578684,0.034937356541939926,0.850739586637804,-0.07505155066878094,0.06190288697562357,0.9934472317916532,0.9276956617640802,1.0638590251438342,0.99 [0.93:1.06],overlaps null,0.003640032952727807,0.0020488309083655986,0.07769601791394402,237.62719915198505,148,4.1228770131590655e-6,0.053381085777467925,0.002577048186500607,TRUE,0,246.54980574186231,0.09235237655549855
ukb-d-30780_irnt,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),LDL direct,MR Egger,149,-0.05916963756725173,0.04560126593898276,0.1964766765738728,-0.14854811880765795,0.030208843673154476,0.9425468642374725,0.8619585297558824,1.0306697603369583,0.94 [0.86:1.03],overlaps null,0.003640032952727807,0.0020488309083655986,0.07769601791394402,232.63202580611156,147,8.610128754080152e-6,0.053381085777467925,0.002577048186500607,TRUE,0,246.54980574186231,0.09235237655549855
ukb-d-30780_irnt,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),LDL direct,Weighted median,149,-0.0352439528361784,0.042100969438475494,0.4025199223590718,-0.11776185293559037,0.04727394726323357,0.9653698828083358,0.8889077181734654,1.0484091785684297,0.97 [0.89:1.05],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-1845,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Mitogen-activated protein kinase 1,Wald ratio,1,-0.02715112796965462,0.03134358155320423,0.3863574444660704,-0.0885845478139349,0.03428229187462567,0.9732141505312263,0.9152257271302505,1.0348767027824417,0.97 [0.92:1.03],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-1845,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Mitogen-activated protein kinase 1,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-2142,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Ornithine decarboxylase,Wald ratio,1,-0.06092560046865846,0.08142940831868775,0.4543386632655126,-0.22052724077328645,0.09867603983596951,0.9408932391880537,0.8020957888544875,1.1037086839891033,0.94 [0.8:1.1],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-2142,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Ornithine decarboxylase,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-1389,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Oxidoreductase HTATIP2,Inverse variance weighted,3,-0.040427908974144056,0.04090458343375564,0.32298289438120453,-0.1206008925043051,0.03974507455601699,0.9603783966797005,0.8863876529637322,1.0405454788603767,0.96 [0.89:1.04],overlaps null,0.010127452427943943,0.022300651570627033,0.7286183729959999,0.2076892757337405,2,0.9013653245830203,0.04624310058353824,1.5673685462641838e-5,TRUE,4.97825285081055e-34,52.75564648462403,0.04580454773166881
prot-a-1389,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Oxidoreductase HTATIP2,MR Egger,3,-0.08103754654726268,0.09833389771842647,0.5611984808986541,-0.27377198607537856,0.11169689298085321,0.9221590669056069,0.7605054613278455,1.1181738829218366,0.92 [0.76:1.12],overlaps null,0.010127452427943943,0.022300651570627033,0.7286183729959999,0.001452875740531918,1,0.9695947103419937,0.04624310058353824,1.5673685462641838e-5,TRUE,4.97825285081055e-34,52.75564648462403,0.04580454773166881
prot-a-1389,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Oxidoreductase HTATIP2,Weighted median,3,-0.04347895508251466,0.0448055114507514,0.3318506319791651,-0.1312977575259874,0.044339847360958085,0.957452703392085,0.8769566150797934,1.0453375497365975,0.96 [0.88:1.05],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-1390,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Oxidoreductase HTATIP2,Wald ratio,1,0.04194655918793849,0.020600089565606806,0.04172707602772575,0.0015703836393491516,0.08232273473652783,1.0428387471121097,1.0015716173374452,1.0858061806597246,1.04 [1:1.09],positive,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-1390,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Oxidoreductase HTATIP2,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ebi-a-GCST90010252,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Paraoxonase activity,Inverse variance weighted,5,-0.010741598865700178,0.023259671103182288,0.6442160326367421,-0.05633055422793746,0.034847356496537106,0.9893158860964837,0.9452266355833417,1.035461640243393,0.99 [0.95:1.04],overlaps null,0.004027165994100067,0.14093376222576295,0.9789982644222213,1.7770569258410893,4,0.7766771462500197,0.2134132020851906,2.3286105789857035e-5,TRUE,1.557444961410361e-71,76.6847438138281,0.22561984675555835
ebi-a-GCST90010252,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Paraoxonase activity,MR Egger,5,-0.014626631813961996,0.13793496404627392,0.9222435277936873,-0.2849791613446589,0.2557258977167349,0.9854798177337182,0.7520299254485221,1.2913987040891513,0.99 [0.75:1.29],overlaps null,0.004027165994100067,0.14093376222576295,0.9789982644222213,1.7762404018102715,3,0.6201188886338472,0.2134132020851906,2.3286105789857035e-5,TRUE,1.557444961410361e-71,76.6847438138281,0.22561984675555835
ebi-a-GCST90010252,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Paraoxonase activity,Weighted median,5,-0.022711045633774244,0.027990132761286438,0.4171390364986617,-0.07757170584589566,0.03214961457834717,0.9775449088369246,0.9253606682481281,1.0326719965330926,0.98 [0.93:1.03],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-2416,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),26S proteasome non-ATPase regulatory subunit 1,Wald ratio,1,0.13808463251670378,0.09613956941351151,0.1509188609777249,-0.05034892353377879,0.32651818856718634,1.1480727104455097,0.9508975760667138,1.3861334613153171,1.15 [0.95:1.39],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-2416,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),26S proteasome non-ATPase regulatory subunit 1,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-2377,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Prolactin receptor,Inverse variance weighted,2,0.02847133539462258,0.054489386023150746,0.6013141832138285,-0.07832786121075287,0.13527053199999803,1.0288805179577973,0.924661216294905,1.1448464600633625,1.03 [0.92:1.14],overlaps null,NA,NA,NA,0.4116248294882184,1,0.5211459561010936,0.025353899808831383,7.044306408804758e-6,TRUE,3.3923276767336344e-19,42.57197397607974,0.02516710765549828
prot-a-2539,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Transforming protein RhoA,Wald ratio,1,-0.022674224741580526,0.026175391797265753,0.38635744446607045,-0.07397799266422139,0.028629543181060348,0.9775809035753025,0.9286921316559718,1.0290433077440186,0.98 [0.93:1.03],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-2539,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Transforming protein RhoA,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ukb-b-998,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Soya dessert intake,Inverse variance weighted,4,-1.4687668043732491,1.4816422780988896,0.3215342322774157,-4.372785669447072,1.4352520607005743,0.2302092031934814,0.012616047434663689,4.200703707673588,0.23 [0.01:4.2],overlaps null,0.028547001926889796,0.04701248307811782,0.6054603894028228,3.055291248365238,3,0.3831786668014104,0.002008404963431262,8.982809906786296e-5,TRUE,2.2065800298374111e-13,32.66097614509072,0.002007662463691091
ukb-b-998,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Soya dessert intake,MR Egger,4,-3.400573572001505,3.591870778575323,0.443701073304285,-10.440640298009138,3.639493154006128,0.033354133475678706,2.9220492467294e-5,38.072534922489474,0.03 [0:38.07],overlaps null,0.028547001926889796,0.04701248307811782,0.6054603894028228,2.579700016477896,2,0.27531207453588513,0.002008404963431262,8.982809906786296e-5,TRUE,2.2065800298374111e-13,32.66097614509072,0.002007662463691091
ukb-b-998,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Soya dessert intake,Weighted median,4,-0.4366688341206445,1.711764711809651,0.798646921705401,-3.7917276692675608,2.9183900010262716,0.6461853905337712,0.02255659782695031,18.51146002347893,0.65 [0.02:18.51],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ukb-d-100920_2105,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Type milk consumed: soya with calcium,Wald ratio,1,-0.5443102568464026,1.8795713556727336,0.7721278063203805,-4.22827011396496,3.139649600272155,0.5802418632003857,0.014577586312219046,23.095772688243102,0.58 [0.01:23.1],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ukb-d-100920_2105,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Type milk consumed: soya with calcium,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ukb-d-1418_4,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Milk type used: Soya,Wald ratio,1,-8.546734184529207,4.855187025014244,0.0783517723916048,-18.062900753557123,0.9694323844987114,1.9417821539556476e-4,1.4301509389218684e-8,2.6364475460632693,0 [0:2.64],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ukb-d-1418_4,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Milk type used: Soya,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-3029,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Tumor necrosis factor,Wald ratio,1,0.030540037243947857,0.08566108007448789,0.7214498747745506,-0.1373556797020484,0.1984357541899441,1.0310111680680951,0.8716601391709717,1.2194936775382808,1.03 [0.87:1.22],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-3029,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Tumor necrosis factor,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-3198,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Vascular endothelial growth factor A,Wald ratio,1,0.04048582995951417,0.03048344844010479,0.1841368157981289,-0.01926172898309122,0.10023338890211955,1.0413165541002438,0.9809225927695684,1.1054288828047532,1.04 [0.98:1.11],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-3198,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Vascular endothelial growth factor A,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
met-d-VLDL_C,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),VLDL cholesterol,Inverse variance weighted,58,-0.021880880916403514,0.0429462282317865,0.610405426748682,-0.10605548825070506,0.06229372641789803,0.9783567690721217,0.8993747419601756,1.0642749044776096,0.98 [0.9:1.06],overlaps null,0.0014332853652499842,0.004576123899212539,0.7552851085118377,100.32793240293913,57,3.48194417892319e-4,0.06766187322927247,0.0011442882725831874,TRUE,0,139.53199836234333,0.06573579648786847
met-d-VLDL_C,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),VLDL cholesterol,MR Egger,58,-0.04230144970623826,0.07826099983128337,0.5909835510276558,-0.19569300937555367,0.11109010996307717,0.9585807731216044,0.8222646234659265,1.1174955998049083,0.96 [0.82:1.12],overlaps null,0.0014332853652499842,0.004576123899212539,0.7552851085118377,100.15248639433167,56,2.649572279219151e-4,0.06766187322927247,0.0011442882725831874,TRUE,0,139.53199836234333,0.06573579648786847
met-d-VLDL_C,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),VLDL cholesterol,Weighted median,58,-0.08174408858896193,0.05260335676459941,0.12019134477686548,-0.18484666784757675,0.02135849066965291,0.9215077528731719,0.83123172863129835,1.0215882158439888,0.92 [0.83:1.02],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ieu-b-4872,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Oestradiol,Wald ratio,1,-0.03157132934725062,0.2768562727374285,0.9092099788786163,-0.5742096239126105,0.5110669652181093,0.9689218414263183,0.5631497930851116,1.6670689509621832,0.97 [0.56:1.67],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ieu-b-4872,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Oestradiol,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-2146,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Oxidized low-density lipoprotein receptor 1,Wald ratio,1,-0.06746861924686193,0.0815899581589958,0.4082806625591084,-0.2273849372384937,0.09244769874476985,0.9347570535361217,0.7966140768398684,1.0968557731263555,0.93 [0.8:1.1],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-2146,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Oxidized low-density lipoprotein receptor 1,NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ebi-a-GCST90012031,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Myeloperoxidase levels,Inverse variance weighted,10,0.03347735305054186,0.04441777748375407,0.4510337877937038,-0.053581490817616116,0.12053619691869982,1.0340440255183205,0.9478286985209669,1.1281015740277045,1.03 [0.95:1.13],overlaps null,0.0010222317718838261,0.008529555085284257,0.9075603340668353,6.183170549380552,9,0.7214550595703795,0.04088243800707527,7.034770916896571e-5,TRUE,2.8612749903060665e-158,92.25123099243628,0.04069396365092959
ebi-a-GCST90012031,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Myeloperoxidase levels,MR Egger,10,0.025033086605306686,0.08329145092393594,0.7714214372674415,-0.13821815720560776,0.1882843304162211,1.025349045282361,0.8709086760168023,1.207176703612453,1.03 [0.87:1.21],overlaps null,0.0010222317718838261,0.008529555085284257,0.9075603340668353,6.168807521827234,8,0.6283292956342219,0.04088243800707527,7.034770916896571e-5,TRUE,2.8612749903060665e-158,92.25123099243628,0.04069396365092959
ebi-a-GCST90012031,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Myeloperoxidase levels,Weighted median,10,0.03320230365007268,0.057416373962058335,0.5630802337038513,-0.07933378931556166,0.14573839661570703,1.033759651439296,0.9237315412615237,1.156893501205389,1.03 [0.92:1.16],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-2866,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),"Steroidogenic acute regulatory protein, mitochondrial",Inverse variance weighted,2,-0.0433177532805929,0.0486346591756287,0.373102687389544,-0.13864168526482515,0.052006178703639355,0.9576070589339881,0.870539899854532,1.0533822510300057,0.96 [0.87:1.05],overlaps null,NA,NA,NA,0.7669313801779524,1,0.3811680316522479,0.027935326216218304,1.580832141754033e-5,TRUE,9.547157228660656e-21,47.1853022912526,0.027818483173691826
ebi-a-GCST90010172,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),"Superoxide dismutase [Mn],mitochondrial levels",Wald ratio,1,-0.006952759859399746,0.0745490362702306,0.9256936336526752,-0.15306887094905172,0.13916335123025222,0.9930713546555883,0.8580706236381401,1.149311826171286,0.99 [0.86:1.15],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ebi-a-GCST90010172,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),"Superoxide dismutase [Mn],mitochondrial levels",NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-2799,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),"Superoxide dismutase [Mn], mitochondrial",Wald ratio,1,-0.009808574592627748,0.021040974529346623,0.6410971038711735,-0.05104888467014713,0.031431735484891636,0.9902393725826077,0.9502322176084973,1.031930928926681,0.99 [0.95:1.03],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
prot-a-2799,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),"Superoxide dismutase [Mn], mitochondrial",NO SENSITIVITY,1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ieu-b-4864,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Total Testosterone,Inverse variance weighted,108,0.008708947493386594,0.04634096085813449,0.8509299904788548,-0.082119335788557,0.09953723077533018,1.008746980706183,0.9211620245403522,1.104659597307645,1.01 [0.92:1.1],overlaps null,-3.117060094065951e-5,0.0029713925679814446,0.9916498764925079,139.78896840130994,107,0.018271925276789287,0.0397183613375478,0.001487593427944154,TRUE,0,81.14004209294677,0.04208526101576542
ieu-b-4864,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Total Testosterone,MR Egger,108,0.009515157077058987,0.08985643772571371,0.9158674789303205,-0.16660346086533986,0.18563377501945785,1.0095605701072474,0.8465352291372159,1.2039812516178996,1.01 [0.85:1.2],overlaps null,-3.117060094065951e-5,0.0029713925679814446,0.9916498764925079,139.78882327810248,106,0.015526215116419073,0.0397183613375478,0.001487593427944154,TRUE,0,81.14004209294677,0.04208526101576542
ieu-b-4864,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Total Testosterone,Weighted median,108,-0.02445448432256153,0.07342410275519064,0.7390905073285354,-0.16836572572273517,0.11945675707761211,0.9758421040220454,0.8450447235708899,1.1268845132340357,0.98 [0.85:1.13],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ieu-b-4869,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Bioavailable Testosterone,Inverse variance weighted,115,-0.03539210281917746,0.05311459591599035,0.5051971367931721,-0.13949671081451853,0.06871250517616362,0.9652268738702574,0.8697958841196873,1.0711282210587574,0.97 [0.87:1.07],overlaps null,-0.0029693099210320525,0.003889761161960394,0.4468361977475458,216.9965851454809,114,2.0832375588780077e-8,0.04712689445718851,0.002319727073249954,TRUE,0,76.61265357465494,0.04775459504347954
ieu-b-4869,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Bioavailable Testosterone,MR Egger,115,0.03969261582200628,0.11183127415580192,0.7233013292419319,-0.17949668152336548,0.2588819131673781,1.0404908945935984,0.835690724158698,1.2954808165689256,1.04 [0.84:1.3],overlaps null,-0.0029693099210320525,0.003889761161960394,0.4468361977475458,215.88330158746305,113,1.959507316470097e-8,0.04712689445718851,0.002319727073249954,TRUE,0,76.61265357465494,0.04775459504347954
ieu-b-4869,ieu-a-1128,ER- Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis),Bioavailable Testosterone,Weighted median,115,0.009589756765901257,0.06628620012291395,0.8849698518104188,-0.12033119547501006,0.1395107090068126,1.0096358858208745,0.8866267413198008,1.1497111179163308,1.01 [0.89:1.15],overlaps null,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
